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Gastrointestinal Stromal Tumors (GIST) are sarcomas driven by gain-of-function mutations 
of KIT or PDGFRA. Although, the introduction of tyrosine kinase inhibitors has 
dramatically changed the history of this disease, evidences emerge that inhibition of KIT or 
PDGFRA are not sufficient to cure patients. The developmental pathway Notch has a critical 
role in the cell fate, regulating cell proliferation and differentiation. Dysregulation of Notch 
pathway has been implicated in a wide variety of cancers functioning as a tumor promoter or 
a tumor suppressor in a cell context dependent manner.  
Given that Notch activation deregulates the morphogenesis of mesenchymal cells in the GI 
track, that Notch acts as a tumor suppressor in neuroendocrine tumors, and finally that the 
cell of origin of GIST are the Interstitial Cell of Cajal that arise from a mesenchymal origin 
with some neuroendocrine features, we hypothesized that Notch pathway signaling may play 
a role in growth, survival and differentiation of GIST cells. To test this hypothesis, we 
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genetically and pharmacologically manipulated the Notch pathway in human GIST cells. In 
this study, we demonstrated that constitutively active intracellular domain of Notch1 (ICN-
1) expression potently induced growth arrest and downregulated KIT expression. We have 
performed a retrospective analysis of 15 primary GIST patients and found that high mRNA 
level of Hes1, a major target gene of Notch pathway, correlated with a significantly longer 
relapse-free survival. 
Therefore, we have established that treatment with the FDA approved histone deacetylase 
inhibitor SAHA (Vorinostat) caused dose-dependent upregulation of Notch1 expression and 
a parallel decrease in viability in these cells. Retroviral silencing of downstream targets of 
Notch with dominant negative Hes-1 as well as pharmacological inhibition of Notch 
pathway with a γ-secretase inhibitor partially rescued GIST cells from SAHA treatment. 
Taken together these results identify anti-tumor effect of Notch1 and a negative cross-talk 
between Notch1 and KIT pathways in GIST. Consequently, we propose that activation of 
this pathway with HDAC inhibitors may be a potential therapeutic strategy for GIST 
patients.	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Chapter 1. Introduction and Background 
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1. Gastrointestinal stromal tumors as a paradigm in translational research  
Gastrointestinal stromal tumors (GIST) are soft tissue sarcomas primarily occurring in the 
stomach (60%) or small intestine (35%), but may also affect the colon, rectum, esophagus or 
retroperitoneum [1, 2]. Their incidence has been estimated to be between ten and 15 cases 
per million people, giving approximately 4,000 to 5,000 new cases annually in the United 
States [3-5]. The median age at diagnostic is 60 years [1] and GISTs rarely affect children 
with less than 3% of cases before the age of 21 years [6]. The term ‘GIST’ was introduced 
by Mazur and Clark in 1983 to distinguish specific stromal tumors from other mesenchymal 
neoplasms of the Gastrointestinal (GI) tract such as leiomyosarcomas (LMS), leiomyomas, 
leiomyoblastoma, and schwannomas [7]. At that time, it was clear that GIST had a specific 
natural history and was generally resistant to conventional chemotherapy and radiation, with 
less than 5% of response in advanced patients [8, 9]. Although some old studies reported 
higher response rates, it is possible to speculate that old studies that have reported higher 
response rates to conventional chemotherapy in GIST included, in fact, some LMS patients.  
Prior the area of target therapies, the majority of GIST patients developed recurrences within 
five years despite complete surgical resection, preferentially into the peritoneal cavity or the 
liver [1]. In this population, the median survival was only 15 months. Long term survivals 
were rare, for example,  a study from MD Anderson Cancer Center (MDACC) has found 
that no more than 10% of patients were disease free after forty months of follow-up [10]. 
The origin of GIST remained controversial until 1998, when Kindblom and colleagues from 
Göteborg University, observed striking morphological and immunophenotypic resemblance 
between GIST cells and the Interstitial Cells of Cajal (ICC), which serve as the pacemaker 
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cell of the gastrointestinal tract [11]. Ultrastructural similarities, including filopodia-like 
cytosplasmic projections, large mitochondria, large Golgi, associated with strong 
immunoreactivity for CD117 (KIT) and CD34 antibodies provided evidences that GIST are 
likely to arise from ICC or ICC precursors.  The same year, Hirota and colleagues, made the 
seminal discovery that the large majority of GIST contain activating mutations in the proto-
oncogene KIT [12]. In this study, on 6 patients with GIST, 5 harbored mutation in the juxta-
membrane domain of KIT. These mutations constitutively activated KIT receptor without 
the requirement of the stem cell factor (SCF) ligand. These ‘gain-of-function’ mutations 
proved to be oncogenic as they induced malignant transformation in a lymphoid cell model, 
suggesting a major role of KIT mutations in GIST development. The functional key role of 
KIT mutations in GIST has been since supported by multiple lines of evidence. First, the 
activated phosphorylated KIT is found by immunohistochemistry in virtually all GIST 
samples [13]. Then, rare patients with germ-line mutations of KIT develop multiple familial 
GIST [14-17]. Engineered mouse models expressing KIT mutations develop GIST-like 
tumors [18, 19].  And lastly, the inhibition of KIT with imatinib resulted in a decrease of 
proliferation of GIST [20]. These findings allowed a major paradigm shift in GIST treatment 
with the possibility to target a specific molecular abnormality resulting in an unprecedented 
clinical success of a targeted therapy in solid tumor. 
 
2. Oncogenic mutations in GIST  
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The proto-oncogene KIT is located on chromosome 4q12 and encodes for a type III 
transmembrane receptor tyrosine kinase.  The gene KIT was first cloned in 1987 as the 
homolog of the Hardy-Zuckerman feline sarcoma virus oncogene v-KIT [22]. The protein of 
145 kilodaltons contains five extracellular immunoglobulin domains involved in ligand 
binding and subsequent homodimerization, a single transmembrane domain, a 
juxtamembrane domain with inhibitory functions, a kinase domain (ATP binding pocket and 
activation loop) separated by a kinase insert and a carboxy-terminal tail region (Figure 1)  
[22].  
 
Figure 1. Schematic illustration of the gene and protein structure of KIT 
KIT is located on chromosome 4q12 and contains 19 exons that encodes for an extracellular 
ligand-binding domain, a juxtamembrane region, an ATP binding site (tyrosine kinase I), a 
kinase insert and an activation loop (tyrosine kinase II). 
 
In normal conditions, SCF binds KIT receptor and activates the kinase domain through 
transphosphorylation of tyrosine residues [23, 24]. Downstream signaling effectors includes 
the three following pathways:  the phosphatidylinositol 3’-Kinase  (PI3K), the mitogen-
activated protein Kinase (MAPK) and Janus kinase/ signal transducers and activators of 
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transcription (JAK/STAT) pathways [13, 25, 26]. AKT activation through PI3K, regulates 
multiple target proteins such as Bad, MDM2, p27, FOXO, and mTOR, leading protein 
translation, survival and proliferation. MAPK pathway activates transcription factor 
including MYC, ELK, CREB, JUN and FOS (Figure 2).  
Figure 2. KIT and PDGFRa signaling in GIST 
KIT activation by ligand binding or gain-of-function mutation, results in activation of 
RAS/RAF, PI3K and STAT pathways. The signal amplification leads changes in gene 
expression through MYC, ELK, CREB, JUN, ETV1 and FOS. In parallel, AKT activation 
modifies protein translation, cell cycle entry and apoptosis.	  
 
In GIST, gain-of-function mutations of KIT result in kinase activation in absence of ligand. 
The gene contains several hotspots, the majority of mutations occuring in exon 11. Those 
mutations disrupt the juxtamembrane domain, forcing the kinase domain to switch into the 
6	  	  
active conformation [27].  Mutations consist of substitutions, deletion, and insertions and are 
found in two thirds of GIST patients [28, 29].  The second most frequent mutations are in 
exon 9 that encodes the extracellular domain of KIT and affect between 8 to 12 % of GIST 
patients [30]. In presence of these mutations, the conformation of KIT changes to mimic the 
homodimerization that occurs after ligand binding [24]. It is important to realize that 
mutations in exon 9 imitate wild-type KIT activation resulting in a more resistant phenotype. 
Clinically, exon 9 mutations are found preferentially in the small and large intestine whereas 
exon 11 mutations are commonly seen in the stomach [31]. Uncommon primary mutations 
(<2%) have been observed in the kinase domain (the ATP binding domain or the activation 
loop) [32]. Of the GIST that not harbor KIT mutation, approximately 30% have a mutually-
exclusive activating mutations of the gene that encode for the receptor for platelet-derived 
growth factor-alpha (PDGFRA) [33-36]. PDGFRA is a homologue of KIT and is located in 
adjacent loci on chromosome 4q. This protein is also a tyrosine kinase receptor with 
comparable functions. Mutations in PDGFRA occur in the juxtamembrane domain (exon 
12), the ATP binding domain (exon 14) or the activation loop (exon 18). It has been reported 
that GIST lacking KIT or PDGFRA mutations may have mutations in BRAF [37]. 
Additionally, defects in succinate dehydrogenase (SDH) complex caused by germ-line 
mutations in SDH genes have been recently described in KIT or PDGFRA wild-type familial 
GIST patients [38, 39]. 
 
3. Chromosomal alterations in GIST 
Although KIT or PDGFRA mutations play a key function during the initiation and 
development of GIST, other molecular alterations have essential roles during tumor 
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progression. This is illustrated by the fact that patients with germline KIT mutations develop 
familial GIST only after the age of 40 years indicating that though the mutation was present 
since birth, this time was required to acquire additional genomic aberrations [17, 40]. An 
additional argument is the description of ‘micro-GIST’ of less than 10 mm in size that are 
frequently found in the general population after surgery or during autopsy (between 2.9-35% 
of all patients) [41-44]. These micro-GIST appear inactive but harbor oncogenic KIT 
mutations indicating that these mutations alone may be insufficient for complete tumor 
progression.   
Investigators have found that almost all adult GIST have cytogenetic aberrations [45, 46]. In 
GIST, losses of chromosomes are more frequent than gains [47]. In particular, loss of 
chromosome 14q, 1p and 22q appear to be frequent in GIST, observed in 40-67% [48-52]. 
This suggests that these three chromosomal regions may contain tumor suppressor genes 
important in malignant transformation of GIST. Clinically, the loss of 1p is most likely to be 
found in intestinal GIST and associated with aggressive clinical outcomes where the loss of 
14p is more characteristic of gastric tumor and favorable prognosis.  Additional losses on 
chromosomes, 9p, 11p, 13q, 15q and 17p have been also reported and are associated with 
malignancy [47]. Gains touch preferentially chromosomes 8q, 3q and 17q [53, 54]. Not 
surprisingly, accumulation of chromosomal alterations correlated with a worse prognosis 
[54]. Based on this observation, a recent study has proposed a gene signature on ‘genome 
complexity’ to classified low and high risk GIST patients [55]. 
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4. Epigenetic alterations in GIST 
The contribution of DNA methylation in the GIST malignancy has been suggested. In one 
study, the hypomethylation of long interspersed nuclear element one (LINE-1), a surrogate 
for global methylation, correlated with aggressiveness of GIST as well as chromosomal 
unbalance [56]. In general in tumors, the global hypomethylation observed in repetitive 
sequences coexists with a regional hypermethylation of CpG islands within specific gene 
promoter regions [57, 58].  In GIST, a genome-wide DNA methylation analysis of GpC 
islands has identified the hypermethylation of REC8, PAX3 and p16 promoter regions and a 
correlation with worse prognosis [59].  
The role of small non-coding RNAs in the development of GIST remains unclear but initial 
data indicate that miR-221, miR-222 and miR-494 are down regulated in GIST and may 
negatively regulate KIT expression [60, 61]. On the other hand, upregulation of miR-196a 
was shown to drive malignant progression in GIST [62]. Additionally, our team has recently 
presented data indicating that Imatinib exposure is associated with differential miRNA 
expression profiles in GIST patient samples. In particular, a miRNA-449b increase was 
noted and appeared to target the pRb-E2F1 pathway [63]. 
  	  
5. Quest for the origin: The Interstitial Cells of Cajal  
The recent success in the management of GIST has been the accomplishment of more than a 
century of research. At the end of the XIX century, the Spanish pathologist Santiago Ramón 
y Cajal using staining with silver chromate and methylene blue identified interstitial cells 
within the muscular layers of the GI wall [64, 65]. In his crucial work, he hypothesized that 
these cells formed a complex system at the interface between the autonomic nervous system 
and the smooth muscle of the GI tract [66]. This initial description was followed early by the 
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intuition that these cells referred as ‘the interstitial cells of Cajal’ represented pacemaker 
cells of the GI track similar to the pacemaker cells of the heart [67, 68]. Nevertheless, the 
rigorous scientific demonstration of a pacemaker function came decades later with the 
development of murine models where ablation of ICC resulted in suppression of the 
electrical slow wave activity [68-71]. A breakthrough came when investigators found that 
ICC expressed the receptor tyrosine kinase KIT (CD117) [72, 73]. This discovery gave a 
tremendous opportunity to gain insight of into the biology of ICC [73, 74]. Developmental 
studies that used to rely only on ultrastructure analysis became much powerful [75, 76].  
Using KIT antibodies, it was now possible to follow the development of ICC within the GI 
track and determined their embryological origin [77]. With an elegant quail and chick 
chimeric model, a study suggested that ICC derived from mesenchymal precursors instead 
of neural crest cells as previously thought [78]. Moreover, the lack of neural crest markers 
gives additional arguments in favor of a mesodermal origin. Immunohistochemical studies 
and confocal images using KIT antibodies revealed different types of ICC [79, 80]. The two 
main ICC are the intramuscular ICC (ICC-IM) within the circular and longitudinal muscle 
layers mediating neurotransmission and the myenteric ICC (ICC-MY) surround the neuronal 
myenteric plexus and generating electrical slow waves (Figure 3). These two populations of 
ICC regulating electrical and secretory signals in the muscular layers confirm remarkably 
the Cajal’s initial vision that the interstitial cells are a complex network at the interface of 
the nervous system and the smooth muscle tissue.  
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Figure 3. Schematic depicting the localization of ICC through the gastrointestinal wall 
layers  
Cartoon showing localization of Intra-muscular ICC (ICC-IM) and Myenteric ICC (ICC-
MY) throughout the GI tract; MP myenteric plexus.    
 	  
As mentioned earlier, the initial observations done in 1998 that GIST cells and ICC shared 
phenotypical similarities leading the hypothesis that ICC are the cell-of-origin of GIST has 
been confirmed by the development of genetically engineered mice model expressing KIT 
mutations. In these mice ICC hyperplasia and GIST-like tumors were observed [18, 19]. 
Additionally, several studies have shown that ICC and GIST have similar gene expressions, 
in particular with high expression of nestin, DOG1, PKCθ, Ano1, and ETV1 [80-86].   
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Importantly, many studies have revealed that GIST expressed a neuroendocrine phenotype 
suggesting a neuroendocrine differentiation [87, 88].  In particular, specific hormone 
production such as synaptic vesicle protein 2 (SV2), synapsine 1, synaptobrevin, 
amphiphysin and ghrelin have been found in GIST. Furthermore, ultrastructural studies by 
electron microscopy showed numerous clear vesicles similar to synaptic-like microvesicles 
(SLMV).  
In addition of ICC, KIT is highly expressed is mast cells, melanocytes, germ cells and 
hematopoietic progenitors [21]. As a result, KIT has critical functions for the developmental 
processes of melanogenesis, gametogenesis and haematopoiesis. 
 
 
6. Association with other primary malignancies  
GIST can be associated with other primary tumors; in particular, in the well characterized 
hereditary conditions such as Carney’s triade (gastric GIST, paraganglioma, and pulmonary 
chondroma), Carney-Stratakis’s dyad (paraganglioma and GIST) and Neurofibromatosis 
type 1 [89-91]. Nevertheless, outside these syndromes, our group reported that GIST may 
often be associated with other neoplasms, in particular, gastric, genitourinary and other 
sarcomas [92]. By studying 783 patients with GIST from MDACC during a 12 year follow-
up, we found that approximately 20% of patients developed additional cancers, a higher 
percentage than that expected in the general population. In a subsequent study, using a large 
international cohort including 10 institutions, we identified and described a new syndrome 
that associated GIST with Desmoid Tumor (DT) [93]. With a statistical analysis, we showed 
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that the associations between GIST and DT were not random. More details of this study are 
provided in the appendix of this dissertation. 
 
7. Targeted therapy in GIST   
 The identification of KIT activation through mutations as the primary oncogenic mechanism 
driving GIST offered a tremendous therapeutic opportunity. Indeed, imatinib mesylate (IM) 
(Gleevec), a tyrosine kinase inhibitor (TKI) had been developed to inhibit the fusion kinase 
BCR-ABL caused by the Philadelphia chromosome translocation in patient with chronic 
myelogenous leukemia (CML) but have also showed activity against KIT and PDGFR-a [94, 
95]. The IC50 of this molecule is 0.1 µM for KIT.  IM is orally available, well absorbed 
with a bioavalability of 98%, and metabolized by cytochrome P450 [96]. The first report of 
clinical response with imatinib in GIST was published in April, 2001. The article described 
the case of a remarkable response in a 50-year-old patient with metastatic GIST [97].  
Following the report, clinical trials were launched and established the efficacy and safety of 
imatinib in a record time. Clinical efficacy results for patients with advanced GIST from 
clinical trials are detailed in Table 1. In February 2002, the US Food and Drugs 
Administration (FDA) approved imatinib for treatment of patients with metastatic and 
unresectable GIST [103].  
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Table 1. Efficacy results from clinical trials in patients with advance GIST. 
 IM : imatinib, PFS: Progression Free survival.  
 
The initial response to imatinib is observed in up to 80% of patients but varies depending 
upon the mutation. Patient harboring a KIT exon 11 mutation experience a significantly 
higher response rate and a longer relapse free survival and overall survival than patient with 
wild-type tumor or exon 9 mutation [107, 108]. Despite the dramatic clinical success, the 
long-term efficacy of imatinib is limited by the development of resistance and tumor 
progression. Secondary resistance to imatinib after initial response is commonly caused by 
secondary mutations of KIT, decreasing imatinib-binding and restoring KIT pathway 
activity [109-112]. These mutations are concentrated in two ‘hotspots’: the ATP binding 
domain pocket, encoded by the exon 13 and 14, and the activation loop encoded by the exon 
17 and 18. Molecular and functional analyses of the different types of secondary mutations 
Study  Year  N IM dose (mg) 
Response 
Rate (%) 
2-year PFS 
(%) Ref 
EORTC 
Phase I  
2001 36 400-1000 56  not reported 
van Oosterom et 
al.[98]  
US B2222 
Phase II 2002 
73 400 50 48 
Demetri et al.[99] 
74 600 58 52 
EORTC 
Phase II  
2003 27 800 70 
73 (1-year 
PFS) 
Verweij et al.[100] 
EORTC 
Phase III 2004 
473 400 50 44 
Verweij et al.[101] 
473 800 51 52 
Intergroup 
S0033 
Phase III 
2008 
345 400 45 41 
Blanke et al.[102] 
349	   800	   45	   46	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have provided a better understanding of structural events that are taking place [113-115]. 
These mutations are different but they all affect the 3 dimensional structure of KIT leading 
to alteration of binding with imatinib. 
The use of imatinib in adjuvant setting following complete resection of primary GIST has 
been subsequently approved by the FDA for delayed tumor recurrence in patients at high 
risk [104]. The recent result from a controlled trial presented by the Scandinavian Sarcoma 
Group demonstrated that the RFS was better for a 3 years adjuvant treatment with IM than 1 
year [105, 106]. As a result, IM 400mg/day for 3 years duration after surgery become the 
new standard for high-risk patients. The optimal duration of adjuvant treatment remains 
unknown but a large increase in relapse was observed after IM discontinuation supporting 
the idea that an even longer duration may have a clinical benefit.  
In the case of imatinib-refractory GIST, the second line TKI,  Sunitinib malate (Sutent), is 
the only FDA-approved treatment, but with limited clinical benefit prior to disease 
progression [116]. Other TKIs, such as nilotinib (Tasigna), sorafenib (Nexavar), dasatinib 
(Sprycel), regorafenib (Stivarga), crenolanib, masitinib are currently tested but due to TKI 
cross-resistances, are unlikely to have a major clinical impact on resistant GIST [117]. For 
those patients, it is crucial to find alternative strategies beyond KIT inhibition. The present 
work proposes to evaluate, in vitro, the role of alternative pathways in the biology of GIST 
cells with the ultimate objective to develop new therapeutic options to treat this tumor. 
 
8. Notch pathway in normal development  
Notch signaling is an extremely evolutionally conserved pathway that contributes in the 
normal development of multicellular organisms by influencing cell-fate decisions during 
15	  	  
embryogenesis and postnatal development [118, 119]. In 1917, Thomas Hunt Morgan was 
the first to described fruit flies with ‘notched’ wings, following two years later by the 
description of a mutation causing this phenotype in a gene termed Notch [120, 121]. It is 
only sixty years later that the fly Notch gene was cloned simultaneously by the teams of 
Artavanis-Tsakonas and Young [122, 123]. The gene encodes a large transmembrane 
polypeptide translated as a full-length protein but subsequently cleaved in the trans-Golgi by 
a furin-like convertase to create a non-covalent heterodimeric receptor [124]. The 
extracellular domain contains several Epidermal Growth Factor (EGF)-like domains and 
cysteine-rich Lin12/Notch repeats (LNR). The cytosplamic part contains a RAM domain, six 
ankyrin repeats (ANK), two nuclear localization sequences (NLS), a transcription 
transactivation domain (TAD) and a C-terminal PEST sequence (Figure 4) [125, 126]. Two 
ligands for the Notch receptor have been described in Drosophila melanogaster, delta and 
serrate. In mammals, the Notch family contains four receptors (Notch1, Notch2, Notch3, 
Notch4) and five ligands (delta-like-1-3-4 and Jagged-1-2) [127-131]. The activation of 
Notch pathway is initiated by the ligand-receptor binding that changes the receptor 
conformation. This three dimensional modification allows two consecutive proteolytic 
cleavages, first by metalloproteases (ADAM10 or ADAM17) and then a γ-secretase 
complex [132]. The γ-secretase complex is composed by the five following subunits: 
nicastrin, presenillin1 and 2, Pen-2 and Aph1 [133, 134]. These cleavages allow the release 
of the intracellular domain of Notch (ICN) into the cytoplasm. The ICN translocates to the 
nucleus and attaches to the transcription factor CSL. In parallel, ICN recruits the co-
activators mastermind-like (MAM) and histone acetyltransferase p300 to remove the 
inhibitory effect of CSL and active the transcriptional activity of Notch targets genes (Figure 
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4 ) [135]. The best characterized Notch targets are from the Hes family (Hairy and Enhancer 
of Split) transcription factors which are basic helix-loop-helix repressors [136, 137]. 
Importantly, in addition of this canonical pathway, several lines of evidences indicate the 
existence of CSL independent Notch signaling [138, 139]. In physiological conditions, the 
Notch pathway participates to balance homeostasis via the control of cell-fate decisions, 
maintenance of undifferentiated state or promotion of differentiation depending on the cell 
context [140]. For example, a forced Notch signaling, in vivo, has shown to prevent 
neurogenesis differentiation and to maintain neural stem-cells. Conversely, in skin, Notch 
activation enhances terminal differentiation and cell-cycle arrest [141-143]. In the digestive 
tract, a recent study has shown that constitutive Notch activity induced mesenchymal cell 
loss and deregulated morphogenesis indicating a probable role of Notch in the development 
of digestive tract mesenchyme [144]. 
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Figure 4. Simplified view of Notch signaling 
A. structure of Notch1 proteins, includes epithelial-growth factor (EGF) like repeats, 
Lin12/Notch repeats (LNR), heterodimerization domain (HD), RAM domain, two nuclear 
localization signals (NLS), six ankyrin repeats (ANK), trans-activation domain (TAD) and a 
PEST sequence. B. canonical Notch signaling is activated following ligand-receptor 
interaction. Two cleavages mediated by metalloproteases and the γ-secretase complex 
liberate the intracellular domain of Notch (ICN) in the cytoplasm.  Before Notch activation 
CSL is bound to DNA with co-repressor (CoR). Then ICN translocates into the nucleus, 
binds CSL and recruits co-activators (HAT, histone acetyltransferase; MAM, masterminde-
like; SKIP, ski-interaction protein) which lead transcriptional activation of Notch target 
genes. The signal ends by ubiquitylation (Ub) of ICN and proteasomal degradation.     
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9. The oncogenic role of Notch signaling   
The oncogenic function of Notch was first described in T-cell acute lymphoblastic 
leukemias (T-ALL). A rare translocation fuses the chromosome 7 and 9 that result in a 
juxtaposition of the T-cell receptor β (TCRβ) gene with a truncated Notch1 gene [145, 146]. 
This translocation occurs in <1% of T-ALL cases, and results in expression of ICN1 that 
leads to activation of the Notch pathway. The oncogenic role of Notch was further 
confirmed by the fact that mice transplanted with hematopoietic progenitor cells expressing 
ICN1 developed T-ALL [147]. In addition, it has been observed that proviral integration, in 
particular the Moloney murine leukemia virus, into Notch genes may also result in T-cell 
leukemia [148, 149].  Nevertheless, the definitive clinical relevance of Notch deregulation in 
T-cell malignancy was confirmed 13 years later by the description of gain-of-function 
mutations in Notch1 occurring in more than 50% of T-ALL [150]. These mutations affect 
the heterodimerization domain and the PEST domain increasing a ligand-independent 
cleavage and ICN1 stability, respectively, resulting in activation of Notch pathway in both 
cases. Furthermore, a recent whole-genome sequencing analysis of chronic lymphoblastic 
leukemia (CLL) has found recurrent activating Notch1 mutations in the PEST domain [151]. 
Although these mutations were less frequent than in T-ALL, they were associated with poor 
prognosis of CLL.  
In solid tumors, the oncogenic role of Notch was originally described in mouse mammary 
tumor virus (MMTV) breast cancer model where retroviral insertions adjacent of Notch4 
(int3) transform mammary cells [152]. In addition, Notch1 has also been found to function 
as an oncogene in mice breast tumor models [153]. In human breast carcinomas, studies 
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reported a high expression of Notch1, Notch ligands and Hes-1 associated with poor overall 
survival [154, 155].  
In non-small cell lung cancer (NSCLC), gain-of-function mutations of Notch1 and a loss of 
Numb, an inhibitor of the Notch pathway, are frequently observed and correlated with poor 
clinical outcomes [156]. Notch3 may also have a role, as a study reported that 40% of 
NSCLC over-expressed Notch3 [157]. Additionally, inhibition of the Notch3 using a 
dominant-negative or by γ-secretase inhibiton, reduced growth in soft agar and increased the 
apoptosis. Similarly, in pancreatic cancer, activation of Notch pathway is frequently found 
in patient samples and seems involved in tumor initiation and maintenance [158, 159]. 
Specific silencing of Notch1 or γ-secretase inhibition reduced pancreatic tumor cell growth 
[160]. Additional studies have implicated Notch pathway in the carcinogenesis, tumor 
maintenance and drug resistance in other solid tumors including colorectal, cervical, ovarian 
cancers and melanomas [161-170].   
Several studies have indicated that the molecular basic for the oncogenic role of Notch may 
be caused by cross-talk with other pathways including Her2, phophatidylinositol 3-kinase / 
AKT, Ras, p53 and β catenin / Wnt signaling [171-175]. These interactions promote various 
oncogenic roles such as cell cycle entry, inhibition of apoptosis, regulation of angiogenesis, 
and epithelial to mesenchymal transformation [176].   
 
10. The tumor suppressive role of Notch signaling   
From studies on the skin, researchers started to understand that the role of Notch pathway is 
not exclusively oncogenic but may suppress tumors in some tissues. Indeed, expression of 
Notch receptors and ligands induced cell-cycle arrest and terminal differentiation in the skin 
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[141, 143, 177].  In consequence, mice with tissue-specific ablation of Notch1 resulted in 
skin hyperplasia and spontaneous basal-cell carcinoma tumors [178]. Consistent with this 
observation, the expression of Notch1, Notch2 and Jag1 are low in human basal cell 
carcinomas.  In addition of basal cell carcinomas, two high-throughput next generation 
sequencing studies fortuitously revealed that 10 to 15% of patients with squamous cell 
carcinomas of the head and neck (HNSCC) arbor inactivating mutations of Notch. In 
addition, loss of heterogeneity (LOH) at the Notch1 locus was detected in some tumors 
analyzed for gene copy number resulting in inactivation of both allele, providing evidence 
for an important tumor suppressor effect of Notch1 in HNSCC [179, 180]. 
A good example of the versatility of Notch signaling in carcinogenesis is in lung cancer.  In 
this organ the impact of Notch pathway is predictable by a dichotomy between 
neuroendocrine and non-neuroendocrine lung tumors. In contrast with what is observed in 
NSCLC, in small-cell lung cancer (SCLC) cell growth is inhibited by an over-expression of 
activated Notch1 and Notch2 [181, 182]. Transduction of intracellular Notch1 leads to an 
increase in Hes1, down-regulation of Mash1 and a potent G1 arrest with p21 induction.  In 
other neuroendocrine tumors (NET) such as carcinoid and medullary thyroid cancer, Notch 
signaling is minimally present and several observations strongly support a tumor suppressor 
role for the Notch pathway [183-185]. Finally, the group of Dr. Zweidler-McKay has 
reported that in B cell malignancies as well as in neuroblastoma, Notch can act as a tumor 
suppressor [186-188]. In those cell lines, expression of constitutively active, truncated forms 
of the 4 Notch receptors (ICN1-4) as well as HES genes inhibited growth and induced 
apoptosis. 	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11. Notch pathway in sarcomas 
Given that the Notch pathway plays a pivotal role in the development of the mesoderm, 
different groups have recently studied the deregulation of this pathway in the 
sarcomagenesis. As it is the case for other malignancies, the role of Notch in sarcomas is 
highly contingent on the cellular context (Table 2). We provide in this paragraph a 
comprehensive review of Notch pathways in sarcomas.  
 
Table 2. Implication of Notch pathway in sarcomas. 
A computational search on PubMed was performed using the keywords: Sarcoma*& Notch 
(September 1st, 2012). On the 81 abstracts evaluated 11 studies were found to be relevant. 
11.1. Notch pathway in Rhabdomyosarcomas 
Sarcomas  Effect  Mechanisms  Ref 
Rhabdomyosarcoma  Oncogene  
Notch1 inhibition reduces proliferation, and 
promotes  differentiation in vitro and in vivo Belyea et al, [189] 
Notch3 inhibition reduces cell growth in vitro 
and in vivo Raimondi et al, [190] 
Notch inhibition via dnMAM reduces 
invasiveness and mobility in vitro Roma et al, [191] 
Hes 1 reverses cellular quiescence and supress 
differentiation in vitro Sang et al, [192] 
Ewing's sarcoma Tumor suppressor  
Activation of Notch1 inhibits cell proliferation in 
vitro Baliko et al, [193] 
Activation of Notch1, 2, 3, Jag1 inhibits cell 
proliferation in vitro 
Bennani-Baiti et al, 
[194] 
Expression of Notch3, Jag1 or Hey1 Induces p53 
and p21 in vitro Ban et al, [195] 
Osteosarcoma  Oncogene   
HES1 increases invasion and metastasis  
Inhibition via CBF1 si RNA suppresses growth 
and induces p21  in vitro and in vivo 
Zhang et al,  
Tanaka et al, [196] 
Inhibition via dnMAM decreases tumor growth 
in vivo Engin et al, [197] 
Angiosarcoma  Tumor suppressor  Notch1 knockout  mice develop angiosarcoma in the liver Dill et al, [198] 
Undifferentiated 
pleomorphic 
sarcoma  
Oncogene  Inhibition of  Notch decrease self-renewal in 
vivo Wang CY et al,[199] 
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Rhabdomyosarcoma (RMS) is the most frequent type of soft tissue sarcoma in children. 
These tumors are divided in two main histologic subtypes: embryonal (60%) and alveolar 
(20%) [200, 201]. Although the exact cell of origin remains uncertain, it is accepted that 
RMS arise from skeletal muscle precursors that failed to differentiate. In normal 
myogenesis, Notch pathway inhibits differentiation and promotes stem cell maintenance 
[202-204]. The first report implicating Notch in RMS tumorigenesis came from a study 
showing that Hes1 controlled the reversibility of cellular quiescence. In this study, Hes1 
mRNA was increased in 21 primary RMS tumors in comparison with skeletal controls. 
Inactivation of Hes1 using a dominant negative Hes1 or a gama-secretase inhibitor (GSI) led 
to differentiation and inhibited proliferation of RMS cells [192]. Subsequent studies 
confirmed the role of Notch pathway in RMS tumorigenesis in vivo, by showing that 
inhibition of Notch via Notch1 shRNA or by GSI decreased tumor growth [189]. The 
pathway has also been implicated in RMS mobility and invasiveness. A recent study has 
found increased expression of Notch2, Notch3, Hes1 and Hey1 in a wide panel of RMS 
primary tumors [191]. In vitro, the genetic and pharmacological inhibition through GSI and 
dominant negative MAM decreased mobility and invasiveness of RMS cells. Additional 
molecular details have been provided by Raimondi et al. They found that inhibition of 
Notch3 induced cell differentiation, hyper-phosphorylation of p38 and increase of p21.  
Notch3 downregulation was sufficient to reduce tumor growth in vitro and in vivo [190]. All 
together, these reports provide evidence for an oncogenic role of Notch in RMS and support 
new therapeutic approaches targeting this pathway. 
11.2. Notch pathway in Ewing’s sarcomas  
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Ewing’s sarcomas family of tumors (ESFT) arises mainly in bone and less commonly in soft 
tissues [205]. The origin of ESFT is a subject of intense debate. The initial thought was in 
favor of a neuroectodermal origin, but many now consider that ESFT arise from a 
mesenchymal stem cell (MSC) with expression of neuroectodermal markers [206]. They are 
characterized by chromosomal translocations that combine EWS and ETS family 
transcription factors. Although that ESFT express Notch receptors, it has been reported that 
Notch was inactive [194, 195]. Additionally, forced expression of activated Notch1, 2 and 3 
induced cell cycle arrest and p21 upregulation. A different study has found a similar result: 
that expression of active Notch-1 reduced the proliferation of ESFT cells [193]. These 
findings suggest tumor suppressor effects of Notch signaling in ESFT. 
11.3. Notch pathway in other sarcomas  
In osteosarcoma (OS), studies found overexpresssion of Notch2, Jagged1, Hey1, and Hey2 
[196, 197] in comparison with normal tissue. Inhibition with GSI, CBF1 siRNA, or dnMAM 
prevented the growth of OS cells and upregulated p21. These findings were replicated in a 
xenograft models and suggested a contribution of Notch in the pathogenesis of OS. 
Additionally, a study identified a critical role of Notch in osteosarcoma invasion and 
metastasis. 
Recent reports have implicated Notch pathway in two additional sarcomas. First, Notch1 
knockout mice developed spontaneous angiosarcoma in the liver endothelium suggesting a 
tumor suppressor effect on Notch1 [198]. Lastly, in undifferentiated pleomorphic sarcomas 
(malignant fibrous histiocytoma), preliminary data suggest that the Notch pathway regulates 
self-renewal of tumor initiating cells [199]. It is important to mention that before the 
publication of the current work, the role of Notch in GIST was unknown. 
24	  	  
  
25	  	  
12. Histone deacetylase inhibitors and Notch pathway   
As mentioned earlier, growing evidence showed that genetic deregulation in cancer are not 
the only events that are essential for cancer formation and progression. In fact, epigenetic 
modifications seem to play a central role in cancer [207, 208]. It has been widely recognized 
that the remodeling of chromatin, and in particular histone modifications including 
acetylation, methylation, phosphorylation, ubiquitination and sumoylation, regulate gene 
expression [209]. In particular, histone acetylation and deacetylation have been shown to 
play a major role in tumor formation. The two enzymes responsible for acetyl modifications 
are the histone deacetylases (HDAC) that remove the acetyl-group and histone 
acetyltransferases (HAT) that acetylate histone tails leading closed state chromatin in the 
first case and open chromatin state in the second (Figure 5).     
 
Figure 5. Role of histone acetyl modifications in gene expression 
Reciprocal reactions, acetylation and deacetylation are catalyzed by histone 
acetyltransferase (HAT) and histone deacetylase (HDAC). Acetylation of chromatin by 
HAT results in open chromatine conformation and transcriptional activation of a subset of 
genes while histone deacetylation by HDAC results in packed chromatin and transcriptional 
repression. Figure modified from Gillet et al. Retrovirology 2007 4:18, Open Access article 
distributed under the terms of the Creative Commons Attribution License.    
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To date, eighteen HDAC have been identified in human and grouped into four classes. Class 
I HDAC includes HDAC-1-2-3 and-8. They are highly conserved and ubiquitously 
expressed. They are involved in many cellular processes such as proliferation, cell cycle, 
apoptosis and DNA damage response. The Class II HDAC contains HDAC -4-5-6-7-9  and -
10. They are generally expressed in a tissue-specific manner and are implicated in the 
developmental process.  The class III HDAC contains Sirtuins. They are broadly expressed 
and have multiple biological functions, such as regulation of oxidative stress, metabolism 
and aging. The class IV HDAC contains HDAC-11 [210]. Aberrant HDAC activities have 
been reported in multiple human cancers. As a result HDAC are currently considered as a 
target to treat cancers with epigenetic aberrations. Two HDAC inhibitors, vorinostat 
(SAHA) and romidepsin are currently approved by the FDA for the treatment of cutaneous 
T cell lymphoma.  Although, the biologic mechanisms of action of HDAC inhibitors are not 
fully understood, a large number of studies have demonstrated that HDAC inhibitors 
induced cell death in a variety of tumors [211, 212]. The death-receptor extrinsic pathway as 
well as the mitochondrial intrinsic death pathway have been shown to be involved in this 
process [213-216]. Importantly, effects on non-histone proteins, including the chaperone 
HSP90 have been characterized [217].  
Suberoylanilide hydroxamic acid (SAHA) is a pan-HDAC inhibitor.  A recent study 
supported that SAHA displayed antiproliferative effects in GIST cells [218].  Furthermore, 
several in vitro studies have shown that diverse histone deacetylase (HDAC) inhibitors up-
regulated Notch1 in various neuroendocrine tumors (carcinoid tumors, pheochromocytomas, 
and medullary thyroid cancers) and in parallel, decreased tumor cell growth [219-222]. 
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These observations support  that HDAC inhibition could be an effective strategy to activate 
the Notch-1 pathway and inhibit growth and hormonal secretion in NET. 
   
13. Rational, significance of the study and specific aims  
 
Although imatinib has dramatically changed the history of GIST treatment, it is clear 
that inhibition of KIT signaling is not enough to cure patients. Primary and secondary 
resistance to TKI in GIST underscore the need for new therapeutic targets beyond KIT. The 
developmental pathway Notch has a critical role in  cell fate, regulating cell proliferation 
and differentiation. Dysregulation of the Notch pathway has been implicated in a wide 
variety of cancers. Given that (i) Notch activation deregulates the morphogenesis of 
mesenchymal cells in the GI track, (ii) Notch acts as a tumor suppressor in neuroendocrine 
tumors, (iii) the cell of origin of GIST are the Interstitial Cell of Cajal that likely arise from a 
mesenchymal origin although sharing common futures with neuroendocrine tumors, we 
hypothesized that Notch pathway may have an inhibitory effect in GIST cells.  In addition, 
given that HDAC inhibitors have been shown to up-regulate Notch1 in neuroendocrine 
tumors, and had antiproliferative effects in these cells, we hypothesized that HDAC 
inhibitors may activate Notch pathway and could offer a therapeutic opportunity to treat 
GIST patients, particularly after failure of tyrosine kinase inhibitors.     
The present study described in this dissertation aspires to explore the role of Notch pathway 
in the pathogenesis of GIST. To address this general objective, we carried out the following 
research aims: 
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Aim 1: To determine the impact of Notch pathway in GIST cells and to examine a 
potential cross-talk between KIT signaling and Notch pathway. 
Aim 2: To determine the relative prognostic potential of Notch pathway members for 
predicting clinical outcome of GIST patients. 
Aim 3: To Investigate the anti-tumor effects of the HDAC inhibitor SAHA and its 
impact on the Notch pathway in vitro. 
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.   
Chapter 2. Material and Methods  
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1. Cell culture  
Three human cell lines have been use in the current study. The GIST-T1, which has 
an imatinib-sensitive KIT mutation in exon 11 (V560-Y579del), was established by Dr. 
Takahiro Taguchi from a patient with metastatic imatinib-naïve GIST [223]. The imatinib-
sensitive cell line GIST882, which has homozygous missense mutations in KIT exon 13 
(K642E), was established by Dr George Demetri from a patient with primary, imatinib-naïve 
GIST [20]. Imatinib-resistant cell line GIST48IM, which harbors homozygous KIT exon 11 
mutations (V560D) and a heterozygous secondary exon 17 mutation (D820A), was 
established by Dr. Jonathan Fletcher from a GIST patient that has progressed on IM, after 
initial clinical response [224]. GIST-T1, GIST882, and GIST48IM cells were kindly 
provided by Drs. Andrew Godwin (Fox Chase Cancer Center), Jonathan Fletcher (Brigham 
And Women's Hospital), and Anette Duensing (University of Pittsburgh Cancer Institute), 
respectively. The p53 status of these cell lines have been recently published, and suggest 
that both GIST-T1 and GIST882 harbor defective p53 with homozygous deletions whereas 
GIST48 cells are wildtype for p53 [225]. KIT mutations were confirmed by direct 
sequencing. Potential contaminations by other cell lines were ruled out using short tandem 
repeated (STR) DNA fingerprinting with an AmpFℓSTR Identifiler kit according to the 
manufacturer’s instructions (Applied Biosystems). STR profiles were compared to known 
fingerprints. Cells were maintained at 37˚C in a humidified incubator containing 95% 
atmospheric air and 5% CO2 as described previously [226]. GIST-T1 and GIST882 cells 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro), supplemented 
with 10% fetal bovine serum (FBS, PAA), and 1% penicillin/streptomycin (Cellgro). 
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GIST48IM cells were maintained in Ham’s media (F-10, Thermo scientific), supplemented 
with 20% FBS, 2 mM L-glutamine (VWR International), 1% penicillin/streptomycin, 0.1% 
amphotericin (Amresco), 10 µg/ml gentamycin (Amresco), 0.5% MITO+ serum extender 
(Becton, Dickinson and Co) and 1% bovine pituitary extract (Becton, Dickinson and Co). 
The cell lines were regularly tested for mycoplasma contamination using MycoAlert 
detection Kit (Lonza).  
 
2. Drug treatment 
Suberoylanilide Hydroxamic Acid (SAHA) and imatinib were purchased from the 
University of Texas-MD Anderson Cancer Center Pharmacy. γ-secretase inhibitor, GSI XXI 
was purchased from Calbiochem. The drugs were dissolved in DMSO (Fisher) at 10 
mMol/L and filtered through 0.22-micron filters, and aliquots were stored in -20°C, 
protected from light.  
 
3. RNA purification, cDNA synthesis and real-time reverse transcription – PCR 
Total RNA was isolated with RNeasy minikit (QIAgen) as described by the manufacturer. 
Samples were desalted and concentrated by centrifugation columns. Omniscript Reverse 
Transcription kit (QIAgen) was used to synthesize cDNA, using 2µl RT buffer, 2µl dNTP 
mix, 1µl oligo-dT primer, 1µl Rnas Inhibitor, 1µl Omniscript Reverse Transcriptase, 
incubated for 60 minutes at 40°C. The newly synthesized cDNA was diluted in a final 
volume of 200 µl.  
Real-time quantitative RT-polymerase chain reaction (RT-PCR) was performed by mixing 
13µl SYBR Green buffer (Bio-Rad), 1 µl of forward and reverse primers (Invitrogen) and 
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RNase-free water to a total volume of 23 µl.  In total, 2 µl of the cDNA template was added 
and the reaction mix heated to 95°C for 10 minutes. Amplification was carried out on an 
ABI5700 (Applied Biosystems) for 40 cycles with a denaturation temperature of 95°C for 15 
secondes and an annealing and extension temperature of 60°C for 1 minute. The genes 
analyzed were: Notch1, Hes1 and KIT. The designed primer sequences are listed in Table 3. 
The reference gene GAPDH was used for normalization. All experiments were performed in 
triplicate at least three times and the results were analyzed using the Ct method and recorded 
as relative expression level [227]. 
Genes  Forward (F) Reverse (R) 
Notch1 5'-CGGGTCCACCAGTTTGAATG-3'  5′-GTTGTATTGGTTCGGCACCAT-3′ 
Hes1  5'-ACGACACCGGATAAACCAAA-3' 5′-CGGAGGTGCTTCACTGTCAT-3′ 
KIT 5′-AGCAAATCCATCCCCACACC-3' 5′-GGCTTGAGCATCTTTACAGCGAC-3′ 
Table 3. List of primer sequences used for RT-Q-PCR. 
 
4. Plasmids and retroviral constructs 
A murine stem cell virus-based retroviral vector MigR1 coexpressing green fluorescent 
protein (GFP) as an expression marker was used to modulate Notch signaling in GIST cells 
(Figure.5) [228]. The intracellular active domain of human Notch1 (ICN1) or full-length 
human Hes1 or Hes5 was inserted into the MigR1 vector. The dominant-negative Hes1 
(dnHes1) and mastermind (dnMAM) were similarly generated as described previously [187, 
229, 230]. All the sequences have been confirmed by sequencing. Plasmids were transfected 
using lipofectamine 2000 (Invitrogen). The viruses were produced with Amphotropic 
Phoenix packaging cells. This cell line is based on the 293T cell line transduced to stably 
produce gag- pol, and envelope proteins. 
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HindIII 16 56
Xba 219 Kpn 403
BglI I 1406
Xho1 1412
Hpa1 1418
EcoR1 1424
Nco1 2017
Sal1 2818HindII I2832Xba1 3103
Kpn1 3287
5' LTR
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GFP
3' LTR
AMP
Ori
MIGR1
6056 bp6231 bp
 
Figure 6. MigR1 sequence 
MSCV-IRES-EGFP retroviral 
construct 
 
 
 
 
 
 
 
 
5. Flow cytometric analysis 
For GFP analysis, adherent GIST cells were trypsinized and suspended in PBS starting 2 
days from transduction. Samples were analyzed with FL-1 channel. For measurement of 
KIT and Notch1 surface expression, adherent cells were resuspended in FACS buffer (PBS, 
2% FBS, 0.1% sosium azide) and incubated with phycoerythrin-conjugated (PE) KIT or a 
Notch1 monoclonal antibody (eBioscience) for 30 minutes. To control for nonspecificity, 
GIST cells were similarly stained with a PE-conjugated isotype anti-IgG1 monoclonal 
antibody (FastImmune). Transduced cells were identified as GFP+.   
For cell-cycle analysis, approximately 3 × 105 cells were cultured with SAHA for 72 
hours. Floating and adherent cells were collected and incubated overnight protected from 
light at 4°C with 0.005% Propidium iodide (PI) and 0.1% Triton X-100 diluted in PBS.  In 
this assay PI binds the cellular DNA to distinguish apoptotic cell populations, and cell-cycle 
phases. Apoptotic cells are identified as hypodiploid cells (sub-G1 phase), where cells with 
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diploid DNA are in G0- or G1-phase, cells with supra-diploid in S-phase, and cells with 
tetraploid DNA are in mitosis or G2. Events were acquired on a FACSCalibur 
flowcytometer or FACSCanto II (Becton, Dickinson and Co.) and resulted were analyzed 
with FlowJo v.7.6 software (Tree Star). Flow cytometic analyses were repeated at least three 
times with consistent results. 
 
6. Analysis of cell proliferation  
Cell proliferation assays were performed using a Promega CellTiter 96 Aqueous 
Nonradioactive Cell Proliferation Assay kit (Promega) according to the manufacturer's 
instructions. This assay detects reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) into formazan, which 
occurs in viable cells after the addition of phenazine methosulfate (PMS). The absorbance 
ABS at 490nm reflects the proportion of living cells in culture. Briefly, 4000 cells/well were 
seeded onto 96-well plates, and incubated at 37°C for 24 hr. Cells were treated with DMSO 
or SAHA (1, 100, 500, 1000, 2000, 10000 nM in a 100 µL volume/well for 72 hr incubation, 
MTS and PMS were combined and added to each well. ABS at 490nm was quantified with 
Bio-Tek microplate reader A3100 (Bio-Tek Instruments) to calculate the percent viability. 
Direct cell counting were done by counting Nuclei (5-25 µm) using an automated Vi-Cell 
Analyzer (Beckman Coulter) as described previously or Mozi Z cell counter (Orflo) [231]. 
These experiments were repeated three times. 
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7. Western blotting analysis 
GIST cells were harvested and washed with PBS; pellets were lysed on ice for 5 minutes in 
a lysis buffer with complete Protease Inhibitor Cocktail (Roche Diagnostic). The protein 
concentration was measured using a Bio-Rad Protein Assay (Bio-Rad). Cell lysates were 
diluted 1:2 with 10 mM DTT sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) loading buffer. Forty micrograms of protein was resolved using SDS-PAGE 
gels and transferred onto polyvinylidene difluoride (PVDF) membranes by using iBlot 
Blotting System (Invitrogen). Membranes were blocked with 5%, non-fat milk dissolved in 
0.05% Tween-20 in PBS (PBS-T) for one hour, and washed thrice with 0.05% PBS-T for 10 
minutes. The membranes were incubated for one hour with primary antibodies in 5% milk-
PBS-T. Membranes were washed with 0.05% PBS-T thrice for 10 minutes before incubation 
with horseradish peroxidase-conjugated secondary antibodies for an hour at room 
temperature as previously described [226, 230]. The primary antibodies used incubated as 
follow: rabbit anti-pKIT (Tyr719) (1:1000, Cell Signaling), rabbit anti-AcH3K9 (1:1000, 
Cell signaling), and rabbit anti-H3 (1:1000, Cell signaling). Actin served as control for equal 
protein loading. Anti-rabbit IgG ECL antibody (1:2000, GE healthcare) was used as a 
secondary antibody. Proteins bands were detected by enhanced chemiluminescence (Thermo 
Scientific).Western blot analysis were repeated at least three times with consistent results. 
 
8. Patients, tumor specimens and study approval  
All GIST specimens were obtained from patients with pre-treated GIST enrolled in a 
previously described IRB approved prospective phase II study of neoadjuvant and adjuvant 
imatinib at MDACC [232]. The diagnoses of GIST were confirmed by experienced soft-
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tissue pathologists on the basis of clinicopathologic evaluation and marker studies. 
Comprehensive patient and tumor variables were recorded and updated into a database until 
December 2011. Tumor size was considered the greatest primary tumor diameter in any 
dimension by computed tomography (CT). Experiments involving recombinant DNA were 
approved by Institutional Biosafety Committees at MDACC and the University of Miami. 
In vivo work was approved by MDACC Animal Care and Use Committee. 
 
9. Gene expression data  
For gene expression analysis, RNA from 37 GIST samples were measured using whole 
human genome oligo arrays with 44-K 60-mer probes (Agilent Technology). Normalization 
values (quantile intensity values) with the median of all samples have been done. Heatmap 
has been generated with Matlab software (MathWorks). Some of these data have been 
previously published [54].    
 
10. Xenograft GIST mouse model 
A retroviral vector encoding Firefly Luciferase and GFP was used for the transduction of 
GIST-T1 cells. Stably transduced cells were sorted and tested, in vitro for light emission in 
presence of D-Luciferin (Xenogen). The orthotopic xenograft model was generated by 
transplantation of GIST-T1-Luc+ cells into the stomach wall of NOD/SCID IL-2-R-gamma 
-/- mice purchased from the Jackson Laboratory. Methoxyflurane-anesthetized mice were 
imaged weekly using a bioluminescence imaging IVIS 200 system (Xenogen). 
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11. Statistical analysis 
For in vitro analysis, the significance of the results was assessed using the Student-t test. All 
experiments were conducted at least three times. Statistical analyses were performed using 
the Prism 5 software program (GraphPad). For patient sample analysis, the relapse-free 
survival (RFS) was defined as the time from surgical resection to disease recurrence; and the 
overall survival (OS) as the time from surgical resection to death. To control for the known 
prognostic factors, the χ2 test was used for categorical variables and the Student-t test for 
continuous variables. To evaluate the association between Hes1 mRNA expression and 
patient outcome, Kaplan-Meier curves were created, and log-rank tests were used to 
compare RFS and OS curves among patients. To evaluate associations between the 
expression of two genes, we used linear regression analyses and Pearson correlation. A 
value of P<0.05 was considered to be statistically significant. 
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Chapter 3. Results: Impact of Notch pathway in GIST 
 
As previously mentioned, the cell of origin of GIST, are ICC or cells in this lineage that 
represent the interface between the neural system of the gut and the endocrine system.  GIST 
and ICC have similar characteristics and particularly some neuroendocrine differentiation 
phenotypes. We, therefore reasoned that Notch signaling may function as a tumor 
suppressor for GIST, as it does for neuroendocrine tumors. We therefore examined the 
impact of Notch signaling in GIST cells and tumor samples since any tumor suppressor 
function might have potential benefits to treat GIST. 
 
1. The active form of Notch1 transduction decreases GIST cell proliferation 
To determine the effect of Notch signaling on GIST cells, we transduced imatinib-sensitive 
GIST-T1 and GIST882 cells, and imatinib-resistant GIST48IM cells with either an empty 
vector expressing GFP alone (MigR1), or co-expressing a constitutively active truncated 
intracellular portion of Notch receptor 1 (ICN1).  We used the percentage of GFP+ cells at 
different times after transduction as an indirect measure of cell growth (Figure.7A). ICN1 
expression potently induced growth arrest in the three GIST cell lines irrespective of their 
sensitivity or resistance to imatinib (Figure.7B). The proportion of GFP+ ICN-expressing 
cells decreased compared to GFP- cells (relative decrease of 93%, 84%, and 95% in GIST-
T1, GIST882, GIST48IM, respectively) 16 days after transduction (P<0.01). In contrast, 
proliferation of cells transduced with control empty vector was not affected. 
Since Hes1 and Hes5 are downstream target molecules of Notch signaling under the control 
of the ICN/CSL/MAML complex and are essential in regulation of neuronal differentiation, 
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we asked whether expression of these is sufficient to recapitulate the inhibitory effect of 
ICN1 in GIST-T1 cells. To answer this question, Hes1 or Hes5 were cloned into MigR1 and 
retrovirally expressed these vectors in GIST-T1 cells. Although the transduction of Hes1 and 
Hes5 into GIST-T1 cells had a growth-inhibitory effect, this effect did not fully recapitulate 
the growth inhibition observed with transduction of ICN-1 (Figure.7C).   
To evaluate the reduced viability in GIST cells, we then examined the morphology of GIST-
T1 and GIST48IM after viral transduction under the microscope. Especially, we confirm 
that the vector alone (MigR1) did not affect the phenotype of the cells. In contrast, the 
forced expression of ICN1, resulted in cellular condensation consistent with typical 
apoptotic cell death (Figure 8). The transduction with Hes5 did not appear to cause cell 
death in the two cells line morphologically observed. 
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Figure 7.  Intracellular domain of Notch1 (ICN1) inhibits GIST cells proliferation 
A.  Representative histograms of GFP (marker for transduced cells) are shown in the three 
GIST cell lines at days 2, 7 and 16 after transduction with MigR1 or ICN1. Three 
independent experiments were performed, and one representative result is shown. GFP, 
green fluorescent protein; MigR1, empty vector; ICN1, intracellular domain of Notch1.   
B. Graph of the percentage of GFP+ GIST cells over time after stable retroviral transduction 
of vector alone (MigR1) or containing ICN1 (normalized to day 2 after transduction). GIST-
T1, GIST882, and GIST48IM cells were transduced with the control vector or ICN1, 
statistical differences: **P<0.01. 
C. Graphs of the percentage of GFP+ GIST-T1 cells over time (normalized to day 2) after 
retroviral transduction with MigR1 alone, Hes1 or Hes5, statistical differences: *P<0.05. 
GFP, green fluorescent protein; MigR1, empty vector; ICN1, intracellular domain of 
Notch1.   
Reprinted from Carcinogenesis. Authors: Amaury G.Dumont, Yanwen Yang , David 
Reynoso, Daniela Katz, Jonathan C.Trent and Dennis P.Hughes. Anti-tumor effects of the 
Notch pathway in gastrointestinal stromal tumors. Copyright 2012, with permission from 
Oxford University Press. 
 
 
 
 
Figure 8. Morphologic features after viral transduction  
GIST-T1 and GIST48IM were transduced with GFP tag vectors and the morphologic 
features were evaluated by microscopy. Representative micrographs of GIST-T1 (left) and 
GIST48IM (right) 6 days after transduction without sorting. Cells were transduced with the 
vector alone (MigR1), ICN1 and Hes5 showing cellular condensation in presence of ICN1. 
Original magnification x200. White arrow: live cells; Red Arrow: dead cells.  
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2. Active form of Notch1 decreases KIT protein expression in GIST cells 
To further elucidate the mechanism of growth arrest in GIST cells, and given that GIST cell 
present a classical phenomenon of oncogene addiction for KIT, we investigated the effects 
of ICN1 forced expression on KIT expression. We transduced the three GIST cell lines with 
either empty MigR1 or MigR1 containing ICN1. Six days after transduction, we analyzed 
the cell-surface KIT expression by flow cytometry using a monoclonal antibody against KIT 
conjugated with phycoerythrin (PE). We observed that activation of Notch1 decreased the 
KIT protein expression in the three GIST cell lines (Figure.9A and Figure.9B).   
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Figure 9. ICN1 decreases KIT protein expression 
A. the GIST cell lines were transduced with MigR1 or ICN1 as described above. After 
transduction, KIT expression on the surface of the cells was evaluated using flow cytometry. 
The KIT expression in the GFP+ (transduced cells) cells is indicated in each cell specific 
gate. KIT expression was lower in GFP+ cells (transduced cells) than GFP- cells (parental 
cell lines) for the constructs containing ICN1 but not for the empty vector. Three 
independent experiments were performed, with similar results: one representative result is 
shown.  
B. comparison of the KIT expression in the GFP+ cells transduced with MigR1 alone and 
ICN1 recorded in Mean Fluorescence Intensity (MFI). A PE-conjugated IgG antibody was 
used as an isotype control (ISO). KIT expression was lower in the ICN1-transduced cells 
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than in the vector control cells. From Dumont et al, copyright 2012, with permission from 
Oxford University Press. 
 
 
3. Dominant negative Hes1 transduction increases KIT protein and mRNA 
expression in GIST-T1 cells 
Since we found that ICN1 forced expression decreased KIT expression, we next determined 
whether a specific Hes1 silencing would impact KIT expression. We blocked Hes1 by 
transducing GIST-T1 cells with a construct containing dominant negative Hes1 (dnHes1) or 
empty vector (MigR1). The inhibition of Hes1 via dnHes1 resulted in a two fold increase in 
KIT protein level and 3 fold increase in mRNA level (Figure. 10A, 10B, and 10C). 
 
 
Figure 10. Effects of Hes1 silencing on KIT expression 
A. comparison of KIT expression in the vector control (MigR1) versus dnHes1 GIST-T1 
cells by flow cytometric analysis.  
B.Western blot analysis of pKIT showing higher protein expression in dnHes1 transduced 
GIST-T1 cells. Actin served as control for equal protein loading. 
C. RT-PCR analysis confirmed that mRNA KIT level was up-regulated in dnHes1 cells. 
Relative KIT mRNA expression levels in relation to GAPDH mRNA levels. Statistical 
difference: **P<0.01. 
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1. GIST patients with high levels of Hes1 mRNA expression have better 
clinical outcomes than patients with low levels of expression 
The previous finding that Notch1 signaling has an anti-tumor effect in GIST cells 
prompted us to determine whether baseline expression of members from this pathway is 
related to relapse-free (RFS) or overall survival (OS) in GIST patients. In particular, as the 
previous data showed an inhibitory effect of Notch1 in GIST cells, we hypothesized that 
expression of Notch family members may be associated with improved clinical outcome in 
patients. We evaluated the clinical predictive value of Notch1 and Hes1 mRNA expression 
by performing quantitative RT-PCR in samples from 15 pre-imatinib GIST patients who 
underwent tumor resection followed by adjuvant treatment with imatinib. Patient 
characteristics are listed in Table 4.  
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Table 4. GIST patient and tumor characteristics (n=15).  
Statistical tests are based on P value calculation. χ2 test was used for binary/categorical 
variables; t-test was used for continuous variables. From Dumont et al, copyright 2012, with 
permission from Oxford University Press. 
 
 
The primary tumor sites were the stomach and small bowel. The Notch1 mRNA transcript 
levels were almost undetectable in all the 15 samples (Figure.11A). In contrast, Hes1 mRNA 
expression was variable in the cohort (Figure.11B). We then performed a Kaplan-Meier 
analysis in the patient cohort after grouping them into two categories, based on Hes1 
expression.  Patients with high Hes1 expression had longer RFS than did those with low 
expression (median of 37 months versus median not reached at >80 months; P=0.005 (log-
rank test)) (Figure. 11C). However, because of the small size of the cohort and small number 
of patient deaths, the difference in overall survival between the two group was not 
significantly different (median not reached at >80 months in either groups) (Figure.11D).  
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In the current cohort some tumors express very low levels of Notch1 mRNA while elevated 
Hes1 mRNA expression. This observation may indicate that Hes1 is uncoupled from 
Notch1. To clarify this point, we used additional gene expression data from 37 GIST 
samples (Figure 12A). We then performed linear regression analyses of mRNA level of 
Hes1 versus several Notch receptors (Notch1, Notch2, Notch4) (Figure 12B). The result 
shows that Hes1 expression do not correlate with Notch receptor expression (Pearson 
correlations, p>0.05). An evaluation of the Notch receptors activation at the protein level 
would be essential to determine in GIST tumors if Hes1 mRNA level is strictly under the 
control of the Notch pathway or alternatively may be regulated by other signaling pathways, 
epigenetic regulations or non-coding RNAs. 
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Figure 11. Hes1 mRNA level predicts the relapse of patients with GIST 
A. Real-time RT-PCR for Notch1 and Hes1 in the 15 GIST samples. Experiments were 
performed in triplicate. The data are presented as the relative expression levels using 
GAPDH (2- ΔCT).  
B. Kaplan-Meier analysis for relapse-free survival (RFS) in GIST patients with high versus 
low Hes1 mRNA expression (n = 15; P = 0.005 (log rank test)). C, Kaplan-Meier analysis 
for overall survival (OS) in GIST patients with high versus low Hes1 mRNA expression (n = 
15; P = not significant (log rank test)).  From Dumont et al, copyright 2012, with permission 
from Oxford University Press. 
 
 
 
 
 
 
. 
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Figure 12. Correlation of Hes1 and Notch receptor mRNA expression in GIST tumor 
samples 
A. Heatmap of gene expression levels from 37 GIST human samples. Relative gene 
expression are show in red (high expression) and green (low expression). 
B. No statistical correlation of Hes1 mRNA level and Notch 1, 2 and 4 mRNA levels was 
found, statistics are by Pearson’s correlation test.  	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Chapter 4. Results: Effects of the histone deacetylase inhibitor 
SAHA in GIST cells 
 
Histone acetylation and deacetylation are processes used by the cell to modulate 
transcriptional activity, cell proliferation, differentiation and apoptosis.  Aberrant expression 
of HDAC has been reported in a number of cancers.  As a result, histone deacetylase 
(HDAC) inhibition appeared to be an appealing strategy in cancer. Although a clinical 
activity has been proven in particular in T-cell lymphoma, the mechanisms of action of 
HDAC inhibitors are not completely elucidated. In neuroendocrine tumors, including 
carcinoid tumors, pheochromocytomas, and medullary thyroid cancers, studies have shown 
that HDAC inhibitors can up-regulate Notch1. In addition, a recent study provided evidence 
that HDAC inhibitors, including suberoylanilide hydroxamic acid (SAHA), display 
antiproliferative effects in GIST cells. SAHA inhibits class I and II histone deacetylases 
[233].  We hypothesized that part of the activity of SAHA in GIST may be through 
modulation of Notch pathway. Here we investigate the anti-tumor effects of the HDAC 
inhibitor SAHA and the impact on the Notch pathway in GIST cells. 	  
1. SAHA up-regulates Notch1 mRNA and protein expression 
To test our hypothesis that treatment with SAHA could up-regulate Notch genes in 
GIST cells, we treated these cells with SAHA by increasing concentrations for 72 hours. We 
found that Notch1 mRNA expression was significantly upregulated in all three cell types 
(Figure.11A). Notch1 mRNA level increase with treatment with 2 µmol/L SAHA (6 and 1.5 
fold increase in GIST-T1 and GIST882 cells, respectively, P<0.05 in both cases). In 
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GIST48IM, treatment with 5 µmol/L SAHA was required to up-regulate Notch1 mRNA 
expression by a two-fold (P<0.05). To determine whether this increased of the Notch1 
transcript level translated to Notch1 protein expression on the surface of these cells, we 
performed flow cytometry analysis using a monoclonal antibody specific for Notch1 protein. 
The flow cytometry analysis indicated that, at the basal level, Notch1 receptor is absent from 
the surface of the GIST cells, and upregulated after treatment with SAHA (Figure.11B). A 
significant up-regulation of Hes1 mRNA expression is also observed after SAHA treatment 
in GIST-T1 and GIST882 (P<0.05) although this up-regulation remains small (Figure.11C). 
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Figure 13. SAHA up-regulates Notch1 mRNA and protein expression 
A. Quantitative RT-PCR analysis of GIST cells treated with increasing doses of SAHA for 
24 hours showing Notch1 mRNA expression. The data are presented as the relative 
expression levels using GAPDH as reference gene and normalized with untreated cells. 
Notch1 mRNA increases after SAHA treatment. Experiments were performed in triplicate, 
and repeated 3 times, the error bars represent standard deviation, statistical differences : * 
P<0.05, **P<0.01. 
B. GIST-T1 and GIST882 cells were treated with 2µmol/L SAHA, and GIST48IM cells 
were treated with 5µmol/L SAHA. Cells were collected 48 hours after drug treatment and 
evaluated for cell-surface Notch1 expression using flow cytometry. Notch1 expression 
increases after SAHA treatment. Three independent experiments were performed with 
similar results; one representative result is shown.   
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C. Quantitative RT-PCR analysis of GIST cells treated with increasing doses of SAHA for 
24 hours showing up-regulation of hes1 mRNA expression. The data are presented as the 
relative expression levels using GAPDH as reference gene and normalized with untreated 
cells; the error bars represent standard deviation. From Dumont et al, Copyright 2012, with 
permission from Oxford University Press. 
 
2. SAHA inhibits cell growth, activates apoptosis, and suppresses KIT 
expression in GIST cells 
To determine the antiproliferative effects of SAHA, we performed colorimetric MTS 
assays to evaluate the GIST cell proliferation after treatment with this HDAC inhibitor. 
Specifically, we treated the GIST cell lines with SAHA at clinically-relevant concentrations 
for 72 hours (100nmol/L to 5µmol/L). Compared with the control group, we found a dose-
dependent growth inhibition in IM-sensitive GIST-T1 and GIST882 cells, and in IM-
resistant GIST48IM cells (Figure.12A).  
To confirm that the antiproliferative effect of SAHA on GIST cells is related to apoptosis, 
we performed cell cycle analysis of detached and attached cells treated with SAHA. We 
found a dose-dependent increase in the number hypodiploid sub-G1 cells for all three cell 
lines (Figure.12B). Notably, in GIST-T1 cells, treatment with 2 µmol/L SAHA resulted in a 
25-fold increase in the sub-G1 population over that in cells treated with control DMSO. In 
GIST48IM cells, the effect of treatment with 2 µmol/L SAHA was minimal and treatment 
with 5 µmol/L was required to achieve a 2.5-fold increase of the sub-G1 population 
compared with control cells.  
In addition, to determine whether SAHA affects KIT expression, we first investigated the 
effects of treatment with SAHA on KIT mRNA level in GIST cells. To prevent the 
confounding late effects of apoptosis on KIT expression, we performed quantitative RT-
PCR analysis to measure the KIT mRNA expression in the three GIST cell line at an early 
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time point (24 hours). In agreement with published findings, KIT mRNA level decreased in 
a dose-dependent manner with treatment with 2 µmol/L SAHA (85% and 62% in GIST-T1 
and GIST882 cells, respectively). In the imatinib resistant GIST 48IM, treatment with 5 
µmol/L SAHA down-regulated KIT mRNA expression by 73% (Figure. 12C). In contrast, 
treatment with imatinib did not decrease KIT mRNA level compared with DMSO control.  
Furthermore, to determine whether the loss of KIT mRNA expression affected KIT 
protein expression and activation, we performed Western blot and flow cytometric analysis 
of the three GIST cell lines after 48 hours of treatment with SAHA. The treatment resulted 
in a decrease of total KIT expression and a complete inhibition of phosphorylated KIT in the 
three cell lines (Figure.12C). As expected, we observed parallel dose-dependent 
hyperacetylation of histone H3 at lys9 in the three cell lines after HDAC inhibitor treatment 
(Figure.12C). 
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Figure 14. Dose-dependent decrease in cell viability, increase in apoptosis, and 
downregulation of KIT expression in GIST cell lines following exposure to SAHA  
A. Exponentially growing GIST cells were exposed to varying concentrations of SAHA. 
Cell proliferation was assessed using an MTS assay 3 days after drug exposure. Points 
represent mean absorbance of triplicate wells relative to DMSO vehicle controls; bars, 
standard deviation. 
B. Results of cell-cycle analysis using propidium iodide (PI) staining and flow cytometry: 
GIST cells were incubated with SAHA at the indicated concentrations for 72 hours. 
Proportion of apoptosis cells estimated by the amount of the hypodiploid DNA peak 
(sub-G1 populations) indicated by the arrows. The experiments were repeated on three 
separate occasions with similar results.  
C. Quantitative RT-PCR analysis of KIT mRNA expression in GIST-T1, GIST882, and 
GIST48IM cells 24hours after increasing doses of SAHA. The histograms show the 
changes in KIT mRNA expression after normalization with GAPDH expression in 
triplicate wells; Bars, standard deviation, statistical differences: **P<0.01. GIST cells 
were treated with SAHA 2 µmol/L for 48 hours and evaluated for cell-surface KIT 
expression by flow cytometry. The Western blot analysis shows the level of 
phosphorylated KIT (P-KIT) and acetylated  Histone H3 (Ac-H3) in GIST cells after 
48hours of SAHA treatment. Actin served as control for equal protein loading. Three 
independent experiments were performed: one representative result is shown. IM, 
imatinib; ISO, isotype control; Ctr, DMSO control. . From Dumont et al, Copyright 
2012, with permission from Oxford University Press. 
 
 
3. Inhibition of Notch pathway partially rescues GIST cells from the effects 
of SAHA treatment  
 
Given that the treatment with HDAC inhibitors potentially affects the expression of 
hundreds of genes, we performed a rescue assay to elucidate the relative contribution of 
upregulation of Notch1 expression to the mechanism of action of SAHA in GIST cells. We 
transduced GIST-T1 cells with dominant negatives dnHes1 and dnMAM and examined 
cells’ viability and KIT expression. To avoid counting dead or dying cells, we assessed cell 
growth by counting the nuclei after chemical lysis of the plasma membrane. After 72 hours 
of treatment with 1 µmol/L SAHA, we observed a significant difference between growth of 
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cells transfected with dnHes1 and vector control (P<0.001) but not with the dnMAM 
construct (Figure.5A). Pharmacological inhibition of Notch activation by a γ-secretase 
inhibitor (GSI XXI) showed a partial rescue of the effect of SAHA in GIST-T1 and 
GIST882 cells. Indeed the addition of GSI XXI decreased the inhibitory effect of SAHA 
alone (P<0.05) (Figure 5B).  
We then studied the KIT cell surface expression after SAHA treatment in cells transduced 
with these constructs. Down-regulation of KIT cell surface expression was partially 
abolished by dnHes1 expression. In contrast, dnMAM did not rescue the KIT protein 
expression after the treatment (Figure.5C). After SAHA treatment, in presence of dnHes1, a 
partial rescue of the KIT expression was found by flow cytometry and western blotting 
(Figure13.C and Figure.13D).  
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Figure 15. Dominant negative Hes1 and γ-secretase inhibitor treatment partially rescue 
the cell growth from SAHA treatment 
A. Growth curve of GIST-T1 cells transduced with dnHes1, dnMAM, and vector alone after 
DMSO control and 1 µmol/L SAHA. The numbers of cells were assessed by automated Vi-
CELL Analyzer. DnHes1 partially rescues the cell growth, while dnMAM does not. Data are 
presented as the mean of three independent experiments +/- standard deviation, statistical 
differences: *P<0.05. 
B. Growth curve of GIST-T1 and GIST882 cells after treatment with SAHA 2 µmol/L alone, 
GSI XXI 100nmol/L alone or in combination of the two drugs.  The numbers of cells were 
assessed by Moxi Z cell counter. Data are presented as the mean of three independent 
experiments +/- standard deviation, statistical differences: *P<0.05. 
C. GIST-T1 cells transduced with a MigR1, dnHes1 and dnMAM cells were treated with 2 
µmol/L SAHA. Cells were collected 48 hours after drug treatment and evaluated for cell-
surface KIT expression using flow cytometry. The KIT expression is rescued by dnHes1 but 
not dnMAM.  Three independent experiments were performed with similar results. 
D. Western blots analysis showing levels of phosphorylated KIT (P-KIT), total Histone H3 
(H3), and acetylated  Histone H3 (Ac-H3) in GIST-T1 cells after 48 hours of SAHA 
treatment. Actin served as control for equal protein loading. Modified from Dumont et al, 
Copyright 2012, with permission from Oxford University Press. 
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Chapter 5. Discussion, future directions and conclusion  
Despite the major success of imatinib in the treatment of GIST, acquired resistances 
mainly caused by secondary mutations of KIT remain a major clinical challenge. Currently, 
second-generation tyrosine kinase inhibitors are used after failure of imatinib, but these 
drugs provide little clinical help prior to disease progression. For those patients, the need for 
new therapeutic strategies beyond KIT inhibition is critical.  
 
1. Impact of Notch1 in GIST 
Notch signaling pathway is an evolutionary highly conserved pathway that regulates 
fundamental cellular functions in multicellular organisms, particularly proliferation, stem 
cell maintenance and differentiation.  Extensive studies have shown that Notch signaling 
regulates cell fate decisions in the intestinal epithelium as well as neural crest-derived tissue 
via Hes family member transcriptional repressors. In cancer, where cells fail to regulate their 
growth within normal homeostasis, studies have implicated the Notch pathway in the 
initiation and progression of different hematological malignancies and solid tumors. 
However, prior to our current work the role of Notch pathway in GIST has not been studied.  
 In the present study, it was established that GIST cell lines and patient samples had very 
low mRNA Notch1 expression.  By constitutively actived Notch1, by viral transduction of 
the intracellular domain of Notch1, in three human GIST cells we observed a growth 
inhibition in GIST cells with diverse KIT mutations and sensitivities to imatinib. It was 
reasonable to speculate that the growth inhibition caused by ICN1 in GIST cells resulted 
from the depletion of KIT. As a result, we demonstrated that KIT expression was down-
regulated in response to Notch1 activation. Interestingly, we found that transduction with a 
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dominant negative of Hes1 increased KIT expression in GIST-T1 cells. Taken together, our 
work suggests a negative interaction between the Notch1 and KIT pathways in GIST. To 
determine the effect of downstream target genes of Notch signaling on GIST biology, we 
tested the effects of Hes1 and Hes5 on GIST-T1 cells. We found that Hes1 or Hes5 alone 
decreased cell proliferation but did not fully recapitulate the profound effect of ICN1 on 
growth inhibition in GIST-T1 cells. This finding may indicate that, although Hes1 and Hes5 
have an inhibitory effect, they may have additive effects, or may not be the only downstream 
targets of ICN1 implicated in this observation.  
To further investigate the mechanism by which ICN1 decreases KIT expression, we 
performed an in silico analysis of the KIT promoter sequence up to 1306bp. This analysis 
revealed the presence of two N-box consensus sequences (CACNAG) at -738,-733bp and -
520,-515 bp that constitute binding site for Hes family members (Figure.14).  
 
Figure 16. N-Box consensus sequences found in the KIT promoter region  
From Dumont et al, copyright 2012, with permission from Oxford University Press. 
 
 
Additionally, epigenetic modifications and microRNA interactions may modulate the level 
and stability of KIT mRNA in a Notch-dependent manner. Further studies are needed to 
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clarify the mechanisms and effectors of Notch-mediated growth inhibition and 
downregulation of KIT expression in GIST cells.  
As previously mentioned, one of the more common cytogenetic aberrations found in GIST is 
the loss of the chromosome 1p region (between 1p36 and 1p13). This deletion is associated 
with aggressiveness in GIST and is less frequently found in other sarcomas such as 
leiomyosarcomas. Interestingly, this region contains the hes2, hes3, hes4 and hes5 genes. It 
was proposed that the deletion of chromosome 1p plays an important role in GIST 
progression by the loss of unknown tumor suppressor genes. Considering our results, we 
envisage that these genes may include Hes family members.  
Having found that Notch1 activation induces growth arrest and downregulates KIT 
expression in GIST cells, we next examined whether difference expressions of  Notch 
signaling members were associated with differences in clinical outcome in patients. Using 
15 pre-treated GIST patient samples we found that the level of Hes1 mRNA expression was 
a prognostic factor for relapse in our cohort. Larger studies with proper controls are needed 
to confirm the prognostic role of Hes1 in GIST. 
 
2. Activity of SAHA in GIST cells  
 
SAHA is an HDAC inhibitor that has been shown to cause in vitro growth arrest, apoptosis, 
and to promote differentiation, as well as to exhibit antitumor activity in patients by re-
inducing expression of tumor suppressor genes and downregulating expression of 
oncogenes. To use clinical relevant concentration of SAHA in our study, we performed a 
review of the pharmacokinetic data available. As we recently pointed out in the journal 
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Cancer Research, the utilization of correct doses for in vivo studies is critical [234].  In the 
case of SAHA, phase I studies have shown that the drug has a linear pharmacokinetic, an 
apparent half-life around 100 minutes and an acceptable bioavailability of 40 to 50%. The 
Cmax after multiple oral administrations ranged between 1.35 and 2.04 µM [235-237].  
Our current study demonstrated that the HDAC inhibitor SAHA can upregulate Notch1 
expression in GIST cells as it was previously observed in neuroendocrine tumors. In our 
work, we established that treatment with SAHA at a concentration of 2 µM decreased 
viability, induced apoptosis, increased Notch1 expression and reduced KIT expression in 
two cell GIST lines. Interestingly, the third cell line GIST48IM that is resistant to IM 
appeared also to be more resistant to SAHA. This apparent cross resistance may reveal drug 
efflux, epigenetic alterations, resistance to apoptosis or pro-survival mechanisms. In this 
case, combination therapy with DNA demethylating agents or Bcl-2 inhibitors, for example, 
could be important in achieving efficacy in GIST.  
The mechanism of action of HDAC inhibitors in GIST cells remained controversial. A 
previous study demonstrated that HDAC inhibitors could deregulated the heat shock protein 
90 (Hsp90), a KIT protein chaperone, and proposed that HDAC inhibitors may silence KIT 
expression via increase of acetylation of HSP90 and a subsequent disruption of KIT at the 
protein level. However, we found in the current study that downregulation of KIT protein 
expression could be the result of the strong decrease of the KIT mRNA level observed by Q-
RT-PCR. Although both events,(the decrease of KIT mRNA level and the loss of HSP90 
chaperone activity) may contribute to the effects of SAHA on GIST cells, we did not 
quantify the respective contributions of these mechanisms. Nevertheless, the profound 
decrease in KIT mRNA transcript level that we observed seems to point out a major 
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transcriptional effect rather than a post-translational regulation. To confirm that SAHA’s 
effect is partially due to its upregulation on the Notch1 pathway, we showed a partial rescue 
of cell growth and KIT expression after Notch inhibition with dnHes1 and the γ-secretase 
inhibitor XXI. 
 
3. Future directions  
In Chapter 3, we have demonstrated that Notch 1 activation decreases cell growth. However 
additional work is required to better understand this observation. The decrease in cell growth 
can be the result of apoptosis, necrosis, quiescence or senescence. To answer this point a 
deeper analyze of apoptosis, senescence and differentiation of the GIST cells after forced 
expression of Notch1 would be important. In particular, a recent study from Kannan et al, 
demonstrated that Hes1 interacted with the Poly ADP-ribose polymerase-1 (PARP1) in a 
cell type-specific manner, ultimately resulting in apoptosis [186]. It would be interesting to 
observe if such a PARP1/Hes1 interaction exists in GIST cells.  
Our gene expression analysis on 37 GIST human samples may indicate that Hes1 is not 
under the strict control of Notch1 as they are not in the same cluster in the Heatmap figure 
12. Nevertheless, it is important to mention that gene expression and protein level rarely 
correlate. Only an immunohistochemistry analysis on tumors samples would address this 
point. The direct demonstration of the activation of the Notch receptors by showing an 
increase of the intracellular domains of those receptors would be critical.   
Our study established that Notch 1 expression results in decreased expression of KIT 
receptor. However, the mechanism is not completely understood. Our data suggest that the 
downregulation of KIT protein is the result of a decrease of KIT mRNA level, but a rigorous 
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demonstration would be required.  The decrease of the mRNA level could be the result of a 
reduction in transcription rate or mRNA stability. To evaluate the transcription rate, a 
nuclear run-assay with radioactive nucleotides would be the best method. To test the 
degradation rate, a study of the mRNA half-life in presence of a transcription inhibitor such 
as actinomycin D could be proposed. 
 We found two consensus sequences for Hes family members in the promotor region of KIT. 
To establish definitely whether Hes family members binds these two putative sites, the gold 
standard would be a chromatine immunoprecipitation (chip) assay using specific primers for 
these binding sites. Alternatively, a mutagenesis site directed assay and reporter luciferase 
assay could be pertinent.  
In the current work, we studied the cross-talk between KIT and Notch exclusively in GIST 
cells.  Investigating whether other tumors have similar negative relationship in tissues where 
KIT is highly expressed, such as hematopoietic stem cells, melanocytes, mast cells, and 
germ cells, would be relevant. Growing evidence points to the limitations of in vitro work, 
in particular, in conventional cell line culture. To address this concern, the impact of Notch 
pathway in GIST could be evaluated with an in vivo model that includes the tumor 
microenvironment. During the time of this study, such model was not available. 
Consequently, we tried to establish a clinically relevant animal model for GIST.  We 
generated an orthotopic xenograft model by a surgical inoculation of human GIST-T1 cells 
into the gastric wall of NOD/SCID Il-2-R-gamma-/- mice. GIST-T1 cells were stably 
transduced to express the luciferase gene in order to allow non-invasive bioluminiscence 
imaging.  The xenografts were established in twelve mice by injecting 1 × 106 cells and 
resulted in a tumor take in nine mice (75%) without dissemination of cells into the abdomen 
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due to the procedure (Figure 17). The luciferase signal increased until the week 5 after 
injection and reached a plateau. Paradoxically, the cells were not able to growth further, and 
invasion was not observed. As a resulted, this model did not completely mimic aggressive 
human GIST and has limited interest. An evaluation of other GIST cell lines available would  
be relevant. The utilization of a knock-in mouse GIST model harboring KIT mutation could 
be an alternative to the xenograft model.  
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Figure 17. Orthotopic mouse model of GIST 
A. Mice were anesthetized and a sub-line of GIST-T1 that express firefly Luciferase was 
implanted into the gastric wall. B. Representative image with stereo microscope. 
C. Mice were monitored using bioluminescence imaging (IVIS) following intraperitoneal 
injection with D-luciferin. Representative images 5 weeks after implantation of luciferase-
expressing GIST-T1 cells into the gastric wall. 
 
 
We have demonstrated in the chapter 4 that SAHA treatment suppresses oncogenic KIT and 
decreased the viability of the cells. Mechanistically, treatment with SAHA reduced KIT 
mRNA levels and up-regulated Notch1 mRNA levels. To confirm the functional activity of 
A B 
C 
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SAHA-induced Notch1 a luciferase reporter assay incorporating binding sites of 
downstream effectors of Notch1 would be required.  
A more comprehensive evaluation of other HDAC inhibitors in GIST, especially more 
selective HDAC inhibitors, would be important to determine if the phenomena described in 
the current study is also valid for other members of this therapeutic class.  
Although HDAC inhibitor treatment resulted in promising in vitro data, results from clinical 
trials in solid tumors have been disappointing. In GIST, the result from a Phase 1 trial of 
imatinib plus panobinostat (LBH589) in third line therapy has been recently presented 
during the American Society of Clinical Oncology annual meeting [238].  In the 12 
extensively pretreated patients receiving the treatment, limited activity on PET scan were 
observed with one partial response and eight stable disease. 
 
4. Conclusion  
In conclusion, in this study, we demonstrated that active form of Notch1 has a growth-
inhibitory effect on GIST cells. Furthermore, in our small cohort, high mRNA Hes1 
expression levels are associated with improved relapse-free survival in patients with resected 
GIST and may be important prognostic markers for GIST. The up-regulation of Notch1 may 
be a therapeutic opportunity for GIST patients as our data suggest that treatment with SAHA 
could increase the mRNA and protein Notch1 expression. Notch1 pathway activation with 
HDAC inhibitors may represent a novel strategy for treatment of GIST, especially after 
tyrosine kinase inhibitor failure. Altogether, our findings provide evidence for a direct 
negative regulation of KIT by Notch1 pathways and support a tumor suppressor of Notch1 
pathway in GIST.  Future studies are needed to characterize the mechanism underlying the 
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crosstalk between KIT and Notch pathways. Nevertheless, our study suggests that the Notch 
pathway represents a potential therapeutic target in GIST.  In the last decade, despite its 
rarity, GIST has been at the center of a paradigm shift in the treatment of solid tumors. We 
hope that discoveries derived from GIST studies will persist to extend beyond this disease to 
influence the oncology field in general.  
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APPENDIX 
A non-random association of gastrointestinal stromal tumor (GIST) and 
desmoid tumor (deep fibromatosis) 
This appendix describes a supplementary work published in the Annals of Oncology [93].  
As patients with GIST are living longer, their risk of developing other malignancies is 
evaluated and reported in the literature. However, the associations between GIST and other 
tumors remain unclear. Most reports described single cases or very small series of patients 
from single institution. GIST have been reported to coexist with gastric, breast, prostate, 
renal, esophagus, colorectal, lung and pancreatic carcinomas; carcinoids; lymphomas and 
melanomas [239, 240]. Additionally, two case reports of a patient with desmoid tumors (DT, 
also known as deep or aggressive fibromatosis) and GIST in the same anatomic location 
were recently reported [241, 242].  Interestingly, DT are very rare sarcomas with a tendency 
for slow, local infiltrative growth where an embryonic conserved signaling pathway, the 
Wnt/β-catenin signaling pathway appears to play an central role in the tumor formation.  
Like the Notch pathway, development studies on Drosophila have described the phenotype 
‘wingless’ and demonstrated that this pathway was  involved in the establishment of the 
body axis as well as the development of many organs.  
In DT nuclear expression of β-catenin has increasingly been used in the differential 
diagnosis of spindle cell neoplasms, particularly in the abdomen [243]. Mutations in the 
CTNNB1 gene, which codes for β-catenin, have been found in the majority of DT patients, 
with most mutations occurring in exon 3 [244-246]. 
DT do not metastasize but can cause significant morbidity through their locally destructive 
effects. Prior trauma, such as previous surgery, is known to increase the risk of sporadic and 
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FAP-associated DT [247, 248]. Complete surgical resection with a wide margin and/or 
radiation therapy constitute the mainstay of resectable DT therapy, while chemotherapy, 
anti-inflammatory agents, tyrosine kinase inhibitors are all treatment options for locally 
advanced DT.  
Anecdotal reports of individuals with GIST and DT led us to evaluate a larger cohort to find 
patients with both tumors, in order to gain insight into whether their simultaneous 
occurrence is a coincidental event.  
 
Material and Methods 
Patients and tumor tissues 
A retrospective analysis was performed from the patient records between 1978 and 2008 at 
The University of Texas - MD Anderson Cancer Center, Helsinki University Central 
Hospital, Fox Chase Cancer Center, Oregon Health & Science University Knight Cancer 
Institute, Cleveland Clinic, Istituto Nazionale dei Tumori, Prince of Wales Hospital, H. Lee 
Moffit Cancer Center, the Armed Forces Institute of Pathology, and Memorial Sloan-
Kettering Cancer Center using a protocol approved by the respective Institutional Review 
Boards. We founded 28 patients with both GIST and DT. Clinical characteristics and 
formalin-fixed, paraffin-embedded GIST and DT specimens accrued were retrieved. 
Specimens were further screened and evaluated by experienced soft-tissue pathologists at 
MD Anderson or Fox Chase who confirmed DT and GIST histology. Demographic and 
clinical information, including treatment, histology and outcome related variables were 
tabulated for analyses. 
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Genomic DNA isolation 
When tissues were available genomic DNA was extracted from 10-µm-thick formalin-fixed, 
paraffin-embedded tissue sections cut from blocks with at least 80% tumor using the 
QIAamp DNA mini kit (Qiagen, Valencia, CA) or the Easy-DNA kit (Invitrogen, Carlsbad, 
CA). 
 
Analysis of KIT, PDGFRA and CTNNB1 mutations  
Polymerase chain reaction (PCR) amplification of DNA for KIT exons 9, 11, 13 and 17; 
PDGFRA exons 12, 14 and 18 and CTNNB1 (β-catenin)  exon 3 was performed.. Each PCR 
amplification was performed in a 50-µl volume containing 10 ng of genomic DNA, 15 µM 
concentrations of each primer, 0.2 mM deoxyribonucleotide triphosphate, 5 µl of 10 x 
reaction buffer, 2.5 mM MgCl2 and 1 unit of AmpliTaq Gold DNA polymerase (Applied 
Biosystems). The KIT and PDGFRA primers were previously published [108, 249].  The 
PCR conditions were as follows: 30 sec at 94˚C; 30 sec at 52˚C and 1 min at 68˚C for 36 
cycles, followed by 10 min extension at 68˚C.  The primers for CTNNB1 exon 3 primers 
were as follows: forward: 5’-TTTGATGGAGTTGGACATGG-3’ and reverse: 5’-
CTGAGAAAATCCCTGTTCCC-3’. The PCR conditions for CTNNB1exon 3 were as 
follows: 30 sec at 94˚C; 30 sec at 55˚C and 1 min at 68˚C for 36 cycles, followed by 10 min 
extension at 68˚C.  PCR products were analyzed in by gel electrophoresis and purified using 
a Qiaquick PCR purification kit (Qiagen). Direct sequencing was carried out from both 
directions using a BigDye Terminator v3.1 cycle sequencing kit on an ABI PRISM 3100 
genetic analyzer (Applied Biosystems). The National Center for Biotechnology Information 
Basic Local Alignment Search Tool was used to analyze both strands to identify mutations. 
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Statistical analysis 
A standardized incidence ratio (SIR) represents a comparison between observations and 
expectations. This ratio is calculated by the number of events observed divided by the 
number of events expected. In this study, SIR was calculated to compare the incidence of 
DT in patients with GIST to the incidence of DT in the general U.S. population from 2000 to 
2008 [250]. We calculated the 95% CIs of SIRs using the formula proposed by 
Vandenbroucke [251]. Overall survival was calculated as the time between the date the first 
neoplasm was diagnosed and the date of death or the last known date at which the patient 
was alive. Survival curves were estimated using the method of Kaplan and Meier method 
and the log-rank test. 
 
Results  
The 28 patients harboring GIST associated with DT were identified as follows: MD 
Anderson Cancer Center (cases 1-4), Helsinki University Central Hospital (cases 5-6), Fox 
Case Cancer Center (cases 7-9), Oregon Health & Science University Knight Cancer 
Institute (case 10), Cleveland Clinic (case 11), Istituto Nazionale dei Tumori (case 12), 
Prince of Wales Hospital (case 13), H. Lee Moffit Cancer Center (cases 14-16), the Armed 
Forces Institute of Pathology (cases 17-23) and Memorial Sloan-Kettering Cancer Center 
(cases 24-28). Table 5 shows the clinical characteristics of this patient population, which 
included 19 men (68%) and 9 women (32%) whose ages ranged from 34 to 88 years.  
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Table 5. Patient and tumor characteristics  
Summary of the 28 patients who developed GIST and DT.GIST, gastrointestinal stromal 
tumor; DT, desmoid tumor; Wt, wild type;  ND, no data; NED, no evidence of disease; 
AWD, alive with disease. Modified from Dumont et al, Copyright 2012, with permission 
from Oxford University Press. 
Case  no.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Age Sex
Primary 
location of
GIST 
Imatinib
KIT or 
PDGFRA  
Mutations 
(GIST) 
Site of DT
B-Catenine 
Mutations 
(Desmoid
Tumor) 
CTNNB1 
Interval 
between 
GIST and 
DT (months) 
Outcome
1 62 M Gastric yes 
KIT mutation 
exon 11: V560D 
Perigastric - 
peripancreatic exon 3:Wt  39 
NED: August 
2009 
2 67 M Gastric yes 
KIT exon 11 
mutation : 
deletion  Gastric exon 3:T41A 35 
NED: February 
2009 
3 50 M Gastric no ND Retrogastric  0 
NED: December 
2007 
4 45 F Omentum yes 
KIT mutation 
exon 11: D579del Colon exon 3 : Wt 39 
AWD: January 
2008 
5 39 F Jejunum yes WT Small bowel exon 3 : Wt 32 
Died on January 
2009 
6 62 F Gastric yes 
KIT exon 
11mutation: del 
Lys 550-Glu556+ 
insLeu 
Right rectus 
abdominis exon 3 : Wt 30 Alive: May 2010 
7 59 F Gastric yes 
KIT exon 
11mutation: 
W557-K558del Small bowel 
exon 3: T41A 
missense 
mutation  42 Alive: May 2010 
8 62 F Jejunum yes 
KIT exon 11 
mutation : del 
556-573 Small bowel exon 3: S45P 16 Alive: May 2010 
9 74 M Gastric yes ND Omentum exon 3: T41A  25 Alive: May 2010 
10 75 M Gastric no 
PDGFRA  exon 
18 mutation: 
D842V Peripancreatic ND 0 
NED: January 
2005 
11 88 F Small intestine no WT Abdominal wall exon 3: Wt -7 
NED: January 
2003 
12 61 M Gastric yes ND Abdominal wall ND 28 Died: July 2004 
13 62 M Gastroduodenal yes 
KIT exon 
11mutation: 
deletion  
Infrapyloric 
mesenteric exon 3: T41A  36 
Died:  March 
2010 
14 42 F Jejunal yes ND Pelvic ND 21 
NED : October 
2006 
15 71 F Gastric yes ND Caudate lobe liver ND 24 Alive : May 2010 
16 52 M Pelvic yes 
KIT exon 9 
mutation Mesenteric ND 30 Alive : May 2010  
17 53 M Gastric no ND Spleen ND 33 ND 
18 75 M Gastric no ND Mesenteric ND 0 ND 
19 65 M Gastric no ND Mesenteric ND 0 Died: July 1988 
20 70 M Gastric no ND Thigh ND 191 NED: March 2003 
21 66 M Gastric no ND Mesenteric ND 0 
NED: January 
2003 
22 42 F Small intestine no ND Mesenteric ND 0 
Alive: January 
2004 
23 40 M Small intestine no ND Mesenteric ND 12 
No follow up 
since 1986 
24 34 M 
Proximal 
Jejunum no 
KIT exon  9 
mutation : 502-3 
AY duplication Terminal ileum ND 19 NED: Oct 2009 
25 58 M Gastric yes ND Mesenteric ND 62 AWD: May 2010 
26 58 M Gastric yes 
KIT exon 11 
mutation : Del 
(6aaDEL 552-7 
MYEVQW) Mesenteric ND 30 AWD: May 2010  
27 54 M Gastric yes 
KIT exon 11 
mutation :  Del 
(557-8 WK del) 
Small 
bowel/mesentery ND 33 NED: April 2010 
28 68 M Small intestine yes ND Proximal jejunum ND 6 Alive: April 2010 
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The majority of patients had sought medical advice because of vague symptoms such as 
epigastric pain, nausea or abdominal discomfort. Interestingly, no cases with a family 
history of FAP were observed. 
In 21 cases (75%), GIST was diagnosed before DT. The average time between these 
diagnoses was 30 months (range, 6 months-16 years). In 6 cases (21%), both tumors 
presented synchronously and in 1 case (case 11; 4%), GIST was diagnosed after DT. The 
primary GIST tumor site was gastric in 17 cases (60%), small intestinal in 9 cases (32%) and 
pelvic or mesenteric in 1 case each (4%). DT involved the extremity in only 1 patient, who 
developed DT of the thigh 16 years after treatment for gastric GIST. In 3 patients (10%), DT 
developed in the surgical incision site and mimicked a recurrence of GIST. 17 patients 
(60%) were treated with imatinib. Ten cases (10, 11, 16-23; (36%)) developed a GIST 
before imatinib therapy was available. A strong family history of GIST (father, brother and 
aunts) was found in case 4, caused by a rare germline mutation of KIT that was previously 
described [252].  
Interestingly, there are reports in the literature investigating the use of imatinib for treating 
DT. Case reports have described responses to imatinib, and a series of 19 patients with DT 
showed a partial response in 3 patients [253-255]. In our series, patient number 2, a 67-year-
old man, received imatinib at 400 mg/day for gastric GIST and developed a DT on the 
posterior wall of the gastric antrum 35 months after the first diagnosis. His dose of imatinib 
was increased to 800 mg/day, resulting in a partial response in both tumors (Fig.ure 18).  
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Figure 18. Partial response observed by Computed Tomography in GIST and DT after 
treatment with Imatinib at 800 mg/day.  
Arrows indicate tumor localization. From Dumont et al, Copyright 2012, with permission 
from Oxford University Press. 
 
The frequency of mutations in KIT and PDGFRA in GIST was similar to that 
previously observed in large cohorts of patients with GIST [256]. KIT was mutated in 11 
cases of 14 (79%), of which 9 cases (64%) were in exon 11 and 2 cases (14%) in exon 9.  
PDGFRA was mutated in 1 case (7%). Two cases (14%) lacked mutations in KIT or 
PDGFRA (wild type). 
β-catenin is commonly deregulated in DT indeed mutations in the CTNNB1 gene have been 
identified with a prevalence of 85% in a large cohort of patients with DT [245]. In our 
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samples available for genotyping, CTNNB1 was mutated in 5 cases (50%) in exon 3 (4 type 
41A and 1 type 45F; Table A1).   
The annual incidence of GIST in the United States is estimated to be 10-15 cases per million 
[257], while the annual incidence of DT is 2-4 cases per million [258]. The expected number 
of DT events in patients with GIST was calculated by applying the DT rate for theoretical 
GIST population in the US. To assess the SIR, only cases from the US from 2000 to 2008 
were used. In this case series, 13 patients were diagnosed with GIST and DT in the US 
between 2000 and 2008. This number was compared to 0.16, an estimated number of 
expected cases assuming the independence of events. The estimated risk of developing DT 
was significantly higher (SIR = 82; 95% CI, 44-133) in GIST patients than in the general 
population.  
Discussion 
To our knowledge, this study was the first to report a series of patients with coexisting GIST 
and DT. This relationship raises the questions about of a potential link between these two 
neoplasms and the possibility of a cancer predisposition syndrome. In our patients who 
developed both tumors there were more men than women (19 vs 9). Accepting the 
possibility of a selection bias in this population, this gender distribution differs from that 
reported in previous GIST and DT studies. The incidence of GIST is equal among men and 
women GIST, and in DT a female predilection is suggested; with a female to male ratios 
commonly ranged between 1.4 and 1.8 [259, 260]. Furthermore, the peak incidence of DT 
has been reported as 25-35 years; however, in our case series, DT occurred at an average of 
59 (range 34-88 years) [258, 260]. Statistical study on this limited population need to be 
interpreted carefully but because these tumors are very rare, the size of this series and the 
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SIR suggest a strong nonrandom association between the distinct tumors. At this stage, we 
can only speculate about this association. 
Although the risk of developing both tumors appears extremely rare, this possibility should 
be considered when the patient has an occurrence of either of these tumors. There are no 
data to support a genetic predisposition syndrome, nevertheless, a germline mutation might 
underlie predisposition for these 2 tumors.  We noted that most of the patients had 
abdominal surgery to remove their GIST and then developed a DT.  It is possible that in 
some of the cases, the surgical trauma latter provokes the desmoid growth. No history of 
FAP was observed in our patients that could explain the increase of risk for developing a 
postoperative DT. The treatment with imatinib does not appear to play a role in the 
development of DT, because several cases in our series were not treated with imatinib. 
Interestingly, there are reports in the literature investigating the use of imatinib for treating 
DT. Case reports have described responses to imatinib, and a series of 19 patients with DT 
showed a partial response in 3 patients.[253-255] Another possibility is that GIST patients 
under physical and radiological surveillance are more likely to have DT detected compared 
to “normal” population. Finally, it is interesting to speculate that circulating stem cell factor 
(KIT ligand) or platelet-derived growth factor in patients with GIST could stimulate the 
growth of DT. Indeed, a cross-talk between the KIT and Wnt signaling pathways has been 
recently described in mast cell leukemia [263]. In this model, nuclear accumulation of β-
catenin was increased by a gain-of-function mutation of KIT [261].  
In this clinical and translational study, we show statistical evidence that there is a 
nonrandom relationship between the concomitant development of GIST and DT. Excluding 
a recurrence of GIST is fundamental for the clinical management of a patient that could 
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potentially still benefit from targeted therapy, such as imatinib. Further investigation is 
needed to establish the link between these tumors and to evaluate possible risk factors for 
their association.  
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